Archive for May, 2020

CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced the appointment of Stephen Webster to its Board of Directors. With nearly 30 years of biotechnology industry experience in raising capital, business development transactions and operations, Mr. Webster has played important roles as the Chief Financial Officer of Spark Therapeutics, Optimer Pharmacuticals and Adolor Corporation. In connection with Mr. Websters arrival, Mitchell Finer, Ph.D., will be stepping down from the Board of Directors effective May 4, 2020 but will continue to serve TCR2 in an advisory capacity.

"We are delighted to welcome in another successful cell and gene therapy executive as Stephen Webster joins our Board of Directors. His distinguished track record of leading companies through periods of growth will prove invaluable at this moment in time as we prepare to present clinical data for our two lead programs, TC-210 and TC-110, and advance a third mono TRuC-T cell therapy towards the clinic," said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics. "His business development transaction expertise will be particularly useful in helping us strike the right partnerships in pursuing our goal of developing innovative T cell therapies for patients suffering from cancer.

Mr. Webster served as the Chief Financial Officer of Spark Therapeutics, a publicly traded gene therapy biotechnology company, from July 2014 until its acquisition by Roche for $4.3 billion in December 2019. He was previously Senior Vice President (SVP) and Chief Financial Officer of Optimer Pharmaceuticals, a publicly traded biotechnology company, from July 2012 until its acquisition by Cubist Pharmaceuticals in October 2013. Prior to joining Optimer, Mr. Webster served as SVP and Chief Financial Officer of Adolor Corporation, a biopharmaceutical company, from 2008 until its acquisition by Cubist Pharmaceuticals in 2011. Mr. Webster also served in leadership positions in the investment banking healthcare groups of Broadpoint Capital and PaineWebber Incorporated.

Mr. Webster has served as a director of Nabriva Therapeutics AG (formerly Nabriva Therapeutics plc), a publicly traded biopharmaceutical company, since August 2016 and Viking Therapeutics, a publicly traded biopharmaceutical company, since May 2014. Mr. Webster received an A.B. in Economics from Dartmouth College and an M.B.A. in Finance from The Wharton School of the University of Pennsylvania.

I am thrilled to become a director of TCR2 Therapeutics, where there is a great opportunity to turn a distinctive TRuC-T cell platform into a series of novel treatments of cancer, said Mr. Webster. I look forward to working with the TCR2 leadership team and Board of Directors to add my business development expertise in helping the Company achieve its goal of bringing transformational therapies to people living with serious solid tumors and hematologic malignancies.

On behalf of TCR2 and the Board of Directors, I would like to thank Mitchell Finer for his many contributions to the rapid growth of our company, added Dr. Menzel. Our strategy to begin with an automated cell therapy manufacturing process benefited from working very closely with Dr. Finer, whose three decades of cell therapy manufacturing leadership provided us a significant competitive advantage in the cell therapy landscape. We look forward to continuing to benefit from his insights as he transitions from a Board member to a consultant.

About TCR2 Therapeutics

TCR2Therapeutics Inc.is a clinical-stage immunotherapy company developing the next generation of novel Tcell therapies for patients suffering from cancer.TCR2sproprietary T cell receptor (TCR) Fusion Construct Tcells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent ofhuman leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release. The Companys lead TRuC-T cell product candidate targeting solid tumors, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Companys lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR2, please visitwww.tcr2.com.

Forward-looking Statements

This press release contains forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "will," "could", "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "seeks," "endeavor," "potential," "continue" or the negative of such words or other similar expressions can be used to identify forward-looking statements. These forward-looking statements include, but are not limited to, express or implied statements regarding the development of the Companys product candidates, future business plans and the therapeutic potential of its product candidates and platform.

The expressed or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical studies and in the availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results from preclinical studies or earlier clinical studies will be predictive of the results of future trials; the expected timing of submissions for regulatory approval or review by governmental authorities, including review under accelerated approval processes; orphan drug designation eligibility; regulatory approvals to conduct trials or to market products; TCR2s ability to maintain sufficient manufacturing capabilities to support its research, development and commercialization efforts, whether TCR2's cash resources will be sufficient to fund TCR2's foreseeable and unforeseeable operating expenses and capital expenditure requirements, the impact of the COVID-19 pandemic on TCR2s ongoing operations; and other risks set forth under the caption "Risk Factors" in TCR2s most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and its other filings with theSecurities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although TCR2believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur.

Moreover, except as required by law, neither TCR2nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Investor and Media Contact:

Carl MauchDirector, Investor Relations and Corporate CommunicationsTCR2 Therapeutics Inc.(617) 949-5667carl.mauch@tcr2.com

Here is the original post:
TCR Therapeutics Announces Veteran Finance Executive Stephen Webster Joins its Board of Directors - GlobeNewswire

The Global CRISPR technology market is expected to reach USD 1,715 million by 2023 from USD 562 million in 2018, at a CAGR of 25%

The rising funding from government and private organizations and the high adoption of CRISPR technology are major factors driving the growth of CRISPR technology market002E

How much is the CRISPR Technology Market worth?

MarketsandMarkets forecasts the CRISPR technology market is expected to reach USD 1,715 million by 2023 from USD 562 million in 2018, at a CAGR of 25% during the forecast period. The global CRISPR services market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World.

In 2018, North America accounted for the largest share of this market majorly due to the rising government and private funding, presence of major pharma and gene therapy companies, and the adoption of CRISPR in a number of applications.

The CRISPR products segment is expected to command the largest share of the CRISPR Products market during the forecast period.

The CRISPR Products market, by product and service, is estimated to be dominated by the products segment in 2018. This is attributed to the fact that the CRISPR Products is being adopted quickly by academics and researchers, pharma and biotech companies.

The enzymes segment is expected to account for the largest share of the products market, being one of the key ingredients in the CRISPR process. Companies like Merck KGaA and Thermo Fisher Scientific are providing hands-on training to researchers, which will increase the demand for CRISPR products in the future.

Download PDF Brochure @ http://www.marketsandmarkets.com/pdfdown=134401204

Biomedical applications to occupy the majority of the market, by application, and grow at the fastest rate during the forecast period.

The biomedical applications segment is projected to be the fastest-growing segment of the CRISPR services market, by application, during the forecast period. Developments in gene therapy, drug discovery, and diagnostics, due to the application of CRISPR, are driving the growth of this biomedical segment.

Many companies have also invested in drug discovery and gene therapy companies that are using CRISPR technology.

North America is expected to account for the largest market share during the forecast period.

North America is estimated to account for the largest share of the CRISPR services market in 2018. This is majorly attributed to the rising government and private funding, presence of major pharma and gene therapy companies, and the adoption of CRISPR in several applications.

Furthermore, crops that are treated with CRISPR-based gene editing are not considered as GMOs in US; this has attracted a number of agricultural companies to focus on the commercialization of CRISPR-edited crops.

Request for Sample Pages @ http://www.marketsandmarkets.com/request=134401204

Who are the leading vendors operating in CRISPR Services Market?

Cellecta, Inc. (US), Thermo Fisher (US), GeneCopoeia, Inc. (US), Applied StemCell (US), Synthego Corporation (US), OriGene Technologies (US), Horizon Discovery (UK), Merck (Germany), and GenScript (US).

Thermo Fisher Scientific has established its presence in diversified life sciences markets; this has helped it to minimize risks and dependency on any business segment. The company has a strong product portfolio and brand image, which enables it to strengthen its position in the market.

The company has initiated a promotional campaign in which it conducts workshops and provides hands-on training to researchers in academic and research institutes working on CRISPR. This campaign is being organized to spread awareness on and promote CRISPR technology.

To speak to our analyst for a discussion on the above findings, clickSpeak to Analyst

This email address is being protected from spambots. You need JavaScript enabled to view it.

See the original post here:
CRISPR Technology Market worth USD 1715 million by 2023 according to a new research report - WhaTech Technology and Markets News

Cancer Gene Therapy Marketis expected to reach 5075 million by 2026 from XX million in 2018 at CAGR of XX %.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/520/

Cancer Gene Therapy Research Report is a method of therapeutic delivery of genetic material into a patients cells as a drug to treat disease and compensate for abnormal genes or to make a beneficial protein. Cancer cells modify themselves (called faults or mutations) in several of their genes which make them divide very often and form a tumor. Gene therapy provides various methods by which doctors can cure cancer like:

Inactivation of a mutated gene that is functioning improperly. Introducing a new gene into the body to help fight a disease. Replacement of mutated gene that causes disease with a healthy copy of the gene.Cancer caused 9.02 million deaths in 2017, and is expected to reach 10 million by 2026; the increased no of cancer prevalence is because of increased body mass index, low fruit and vegetable intake, lack of physical activity, increased tobacco and alcohol consumption. Also, Factors like increasing ethical acceptance of gene therapy for treatment of diseases and growing popularity of DNA vaccines, High success rate during the preclinical and clinical trial, Increase in funding for R&D in cancer gene therapy, Increase in geriatric population, favorable government regulations will fuel the global Cancer Gene therapy market. However, the high cost of gene therapy treatment and unwanted immune responses will restrain market growth.The highest revenue-generating region is North America in 2017 followed by Europe; reasons behind this increased growth rate are well-established health care facilities, high per capita health care expenditure, and extensive R&D activities for the gene therapy in the region. However, Asia Pacific is projected to expand at a moderate growth rate during the forecast period.

Key Highlights:

Assessment of market definition along with the identification of key players and an analysis of their strategies to determine the competitive outlook of the market, opportunities, drivers, restraints, and challenges for this market during the forecast period Comprehensive analysis of factors instrumental in changing the market scenario, rising prospective opportunities, market shares, growth strategies that can In-depth analysis of the industry on the basis of market segments, market dynamics, market size, competition & companies involved value chain Cancer Gene Therapy market analysis and comprehensive segmentation with respect to the therapy and geography to assist in strategic business planning Cancer Gene Therapy market Research Report analysis and forecast for five major geographies North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and their key countries Complete quantitative analysis of the industry from 2017 to 2026 to enable the stakeholders to capitalize on the prevailing market opportunities.For company profiles, 2017 has been considered as the base year. In cases, wherein information was unavailable for the base year, the years prior to it have been considered.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/520/

Research Methodology:

An objective of the study is to estimate the size of the Cancer Gene Therapy market for 2017 and projects its demand till 2026 with quantitative and qualitative analysis of Cancer Gene Therapy market. Industry experts have studied various industry journals, directories, have referred information available with various associations to identify, collect information and to put it in articulated format to make useful for all stake holders in the industry. Primary research has been done and various industry experts and suppliers from worlds wide have given their inputs to make the study more accurate.Key Players in the Cancer Gene Therapy Market Are:

Shenzhen Sibiono Genetech Adaptimmune Glaxosmithkline Oncogenex Pharmaceuticals Bluebird Bio, Inc. Synergene Therapeutics Shanghai Sunway Biotech Biocancell Celgene MerckKey Target Audience:

Cancer Gene Therapy Market Investors Cancer Gene Therapy Marketing Players Pharmaceutical and Biotechnology Companies Healthcare Institutions (Individual Surgeons, Medical Schools, Group Practices, Hospitals, and Governing Bodies) Diabetes Drugs Market Research Associations Diabetes drug Manufacturers & DistributorsScope of the Cancer Gene Therapy Market

Research report categorizes the Cancer Gene Therapy market based on Therapy and geography (region wise). Market size by value is estimated and forecasted with the revenues of leading companies operating in the Cancer Gene Therapy market with key developments in companies and market trendsCancer Gene Therapy Market, By Therapy:

Oncolytic Virotherapyo Adenoo Lentiviruso Retro Viruso Adeno Associated Viruso Herpes Simplex Viruso Alpha Viruso Vaccinia Viruso Simian Viruso Others Gene Transfero Naked Plasmid Vectoro Electroporationo Sonoportiono Magnetofectiono Gene Gun Gene-Induced Immunotherapyo Delivery of Cytokines Geneo Delivery of Tumor Antigen GeneCancer Gene Therapy Market, By Geography:

North America Europe Asia Pacific Middle East & Africa Latin America

MAJOR TOC OF THE REPORT

Chapter One: Cancer Gene Therapy Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Cancer Gene Therapy Market Competition, by Players

Chapter Four: Global Cancer Gene Therapy Market Size by Regions

Chapter Five: North America Cancer Gene Therapy Revenue by Countries

Chapter Six: Europe Cancer Gene Therapy Revenue by Countries

Chapter Seven: Asia-Pacific Cancer Gene Therapy Revenue by Countries

Chapter Eight: South America Cancer Gene Therapy Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Cancer Gene Therapy by Countries

Chapter Ten: Global Cancer Gene Therapy Market Segment by Type

Chapter Eleven: Global Cancer Gene Therapy Market Segment by Application

Chapter Twelve: Global Cancer Gene Therapy Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Cancer Gene Therapy Market Report at:https://www.maximizemarketresearch.com/market-report/cancer-gene-therapy-market/520/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Originally posted here:
Cancer Gene Therapy Market : Research Report - MR Invasion

The report aims to provide an overview of Global Assistive Technologies for Visual Impairment Market along with detailed segmentation of market by applications, end-users and five major geographical regions. Global Assistive Technologies for Visual Impairment market is expected to witness an aggressive growth during the forecast period.

Leading players of Assistive Technologies for Visual Impairment Market:VFO Group, TQM, Humanware, Handy Tech Elektronik GmbH, Perkins Solutions, Papenmeier, Amedia, Eurobraille, Nippon Telesoft, Brailletec, VisionCue

Get Sample Copy of this Report @ https://www.reportsweb.com/inquiry&RW00013377966/sample

The Global Assistive Technologies for Visual Impairment Market Analysis to 2025 is a specialized and in-depth study of the Assistive Technologies for Visual Impairment market with a focus on the global market trend. The report aims to provide an overview of the global Assistive Technologies for Visual Impairment market with detailed market segmentation by service, technology, industry vertical, and geography. The global Assistive Technologies for Visual Impairment market is expected to witness high growth during the forecast period.

Segmentation by Type:Braille Displays

Note Takers

Magnifiers

Braille Printers and Embossers

Braille Writers

Segmentation by Application:Blind School

Disabled Persons Federation and Hospital

Enterprises and Social Organizations

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global Assistive Technologies for Visual Impairment market based on the service, technology, and industry vertical. It also provides market size and forecast till 2025 for overall Assistive Technologies for Visual Impairment market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America (SAM).

Get Discount for This Report @ https://www.reportsweb.com/inquiry&RW00013377966/discount

The report evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend and provides exhaustive PEST analysis for all five regions.

What the report features:-

Reason to Buy:

Purchase This Report @ https://www.reportsweb.com/inquiry&RW00013377966/buying

About ReportsWeb:ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us:Call: +1-646-491-9876Email: [emailprotected]

View post:
Exclusive Research Report on Assistive Technologies for Visual Impairment Market, Size, Analytical Overview, Growth Factors, Demand and Trends...

The Enzyme Replacement Therapy Market report market intelligence study intended to offer complete understanding of global market scenario with the Impact of COVID-19 (Corona Virus). It attempts to analyze the major components of the Market which have greater influence on it. This includes various elements of significant nature including market overview, segmentation, competition landscape, Market chain analysis, key players stratergyand more. Also, the report provides a 360-degree overview of global market on the basis of various analysis techniques including SWOT and Porters Five Forces. Approximations associated with the market values over the forecast period are based on empirical research and data collected through both primary and secondary sources. This might help readers to understand the strengths, opportunities, challenges and perceived threats of the market.

Based on Classification, each type is studied as Sales, Market Share (%), Revenue (Million USD), Price, Gross Margin and more similar information. The report can help to realize the market and strategize for business expansion accordingly. In the strategy analysis, it gives insights from marketing channel and market positioning to potential growth strategies, providing in-depth analysis for new entrants or exists competitors in the Enzyme Replacement Therapy industry.

The Enzyme Replacement Therapy Market report wraps:

There are 13 Chapters to thoroughly display the Enzyme Replacement Therapy market. This report included the analysis of market overview, market characteristics, industry chain, competition landscape, historical and future data by types, applications and regions.

In the end, The objective of the market research report is the current status of the market and in accordance classifies it into a few objects. The report takes into consideration the first market players in every area from over the globe.

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Originally posted here:
Enzyme Replacement Therapy Market Forecast: By Regions, Type and Application with Sales and Revenue Analysis 2020-2026 - Latest Herald

Facts & Factors Market Research, a leading market research and consulting firm added the latest industry outlook report on Cancer Gene Therapy Market By Type (Ex-vivo and In-vivo) and By Product (Viral Vectors, Non-viral Vectors, and Others): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 20202026 consisting of 190+ pages during the forecast period 2019 to 2026 and the Cancer Gene Therapy Market report offers comprehensive research updates and information related to market growth, demand, and opportunities in the Cancer Gene Therapy Market.

The Cancer Gene Therapy Market report provides an enormous info as well as sensible details based on the certainties Cancer Gene Therapy Market. The market report on Cancer Gene Therapy provides a profound sector forecast in perspective of the provincial evaluation via detailed assessment within the time span. It, in addition, passes on expansive information of the marketplace key players, sub traders, merchants, along with other supplementary sources.

It gives a forward-looking factor of view on diverse elements using or restricting enterprise quarter development. It offers a forecast based on how the marketplace is predicted to increase. Their key financials, widespread business enterprise assessment, weighted SWOT examination, key improvements, developments, land unfold, and methods are contemplated and were skillfully made on this a long way reaching Cancer Gene Therapy market file.

Request Free Sample Copy of Cancer Gene Therapy Market Research Report @ http://www.fnfresearch.com/sample/cancer-gene-therapy-market-by-type-ex-vivo-898

Benefits of Requesting a FREE Sample Report Before Purchase:

How this report helps you?

The reports will help in performance enhancement and quicker and right decision-making.

The Major Market Players Dominating this Cancer Gene Therapy Market for its Products, Services, and Continuous Product Developments are:

Vigene Biosciences, Sirion Biotech, Bluebird bio, Cellectis, Ziopharm, Cobra, Uniqure, Finvector, Sarepta Therapeutics

Request Customized Copy of Report @ http://www.fnfresearch.com/customization/cancer-gene-therapy-market-by-type-ex-vivo-898

(We customize your report according to your research need. Ask our sales team for report customization).

Customization Options:

The Cancer Gene Therapy Market can be customized to the country level or any other market segment. Besides this, Report understands that you may have your own business need, hence we also provide fully customized solutions to clients.

The Cancer Gene Therapy market record covers a top to the bottom focused scene in which key giants are profiled. Exclusive manufacturers engaged with the Cancer Gene Therapy market are surveyed. The research report for the Cancer Gene Therapy market incorporates a global point of view. This report investigates Cancer Gene Therapy market size and trends primarily based on its marketplace fragments, chief geologies, and modern marketplace patterns. This may bolster the consumer in settling on knowledgeable choices and primary key systems.

Inquire more about this report before purchase @ http://www.fnfresearch.com/inquiry/cancer-gene-therapy-market-by-type-ex-vivo-898

(You may enquire a report quote OR available discount offers to our sales team before purchase).

The report hands in-depth segmentation of the worldwide market based on supported technology, product type, application, and numerous processes and systems. The report attains economical competitive analysis, business trends within the market, and an alternative key characteristic of the worldwide Cancer Gene Therapy market. Our experts have genuinely concatenated the Cancer Gene Therapy market share report by alluding the lists and figures, primary sources, to boost the understanding of the associated procedural terms and conditions.

(To get a full list of major market profiles, request a free sample page here)

The Cancer Gene Therapy market size report includes the leading advancements and technological up-gradation that engages the user to inhabit with fine business selections, define their future-based priority growth plans, and to implement the necessary actions. The global Cancer Gene Therapy market report also offers a detailed summary of key players and their manufacturing procedure with statistical data and profound analysis of the products, contribution, and revenue.

Exclusive manufacturers engaged with the Cancer Gene Therapy market share are surveyed. Their key financials, preferred enterprise assessment, weighted SWOT exam, key advancements, traits, land unfold, and approaches are pondered and had been skillfully made on this far-reaching Cancer Gene Therapy market document. The Cancer Gene Therapy market record covers a top to the bottom focused scene in which key giants are profiled. Exclusive manufacturers engaged with the Cancer Gene Therapy are surveyed. The research report for the Cancer Gene Therapy market incorporates a global point of view. This report investigates Cancer Gene Therapy market trends primarily based on its marketplace fragments, chief geologies, and modern marketplace patterns. This may bolster the consumer in settling on knowledgeable choices and primary key systems.

Top Reasons to Buy the Report:

Regions and Countries Level Analysis

Regional analysis is another highly comprehensive part of the research and analysis study of the Cancer Gene Therapy market presented in the report. This section sheds light on the sales growth of different regional and country-level Cancer Gene Therapy markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the Cancer Gene Therapy market.

For in-depth Report, Details Visit Report Page: http://www.fnfresearch.com/cancer-gene-therapy-market-by-type-ex-vivo-898

Some important key factors included in the report:

About Us:

Facts & Factors is a leading market research company and offers customized research reports and consulting services. Facts & Factors aims at management consulting, industry chain research, and advanced research to assist our clients by providing planned revenue model for their business. Our report and services are used by prestigious academic institutions, start-ups, and companies ly to understand the international and regional business background. Our wide-ranging database offers statistics and detailed analysis of different industries worldwide that help the clients in achieving sustainable progress. The well-organized reports help clients in developing strategies and making informed business decisions.

Contact Us:

Facts & Factors

Headquarters

Level 8, International Finance Center, Tower 2,

8 Century Avenue, Shanghai,

Postal 200120, China

Tel: +8621 80360450

E-Mail: sales@fnfresearch.com

Web: http://www.fnfresearch.com

Go here to see the original:
Cancer Gene Therapy Market Size, Share, Growth Drivers Analysis in a new research report Forecast 2020-2026 - Northwest Trail

Shandong Huge

Global Dental Consumables And Dental Instruments Market: Competitive Landscape

This section of the report lists various major manufacturers in the market. The competitive analysis helps the reader understand the strategies and collaborations that players focus on in order to survive in the market. The reader can identify the players fingerprints by knowing the companys total sales, the companys total price, and its production by company over the 2020-2026 forecast period.

Global Dental Consumables And Dental Instruments Market: Regional Analysis

The report provides a thorough assessment of the growth and other aspects of the Dental Consumables And Dental Instruments market in key regions, including the United States, Canada, Italy, Russia, China, Japan, Germany, and the United Kingdom United Kingdom, South Korea, France, Taiwan, Southeast Asia, Mexico, India and Brazil, etc. The main regions covered by the report are North America, Europe, the Asia-Pacific region and Latin America.

The Dental Consumables And Dental Instruments market report was prepared after various factors determining regional growth, such as the economic, environmental, technological, social and political status of the region concerned, were observed and examined. The analysts examined sales, production, and manufacturer data for each region. This section analyzes sales and volume by region for the forecast period from 2020 to 2026. These analyzes help the reader understand the potential value of investments in a particular country / region.

We Offer up to 30% Discount @ https://www.marketresearchintellect.com/ask-for-discount/?rid=180696&utm_source=LHN&utm_medium=888

Key Benefits for Stakeholders:

The report provides an in-depth analysis of the size of the Dental Consumables And Dental Instruments world market, as well as recent trends and future estimates, in order to clarify the upcoming investment pockets.

The report provides data on key growth drivers, constraints and opportunities, as well as their impact assessment on the size of the Dental Consumables And Dental Instruments market.

Porters 5 Strength Rating shows how effective buyers and suppliers are in the industry.

The quantitative analysis of the Dental Consumables And Dental Instruments world industry from 2020 to 2026 is provided to determine the potential of the Dental Consumables And Dental Instruments market.

This Dental Consumables And Dental Instruments Market Report Answers To Your Following Questions:

Who are the main global players in this Dental Consumables And Dental Instruments market? What is the profile of your company, its product information, its contact details?

What was the status of the global market? What was the capacity, the production value, the cost and the profit of the market?

What are the forecasts of the global industry taking into account the capacity, the production and the value of production? How high is the cost and profit estimate? What will be the market share, supply, and consumption? What about imports and export?

What is market chain analysis by upstream raw materials and downstream industry?

Get Complete Report @ https://www.marketresearchintellect.com/need-customization/?rid=180696&utm_source=LHN&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Dental Consumables And Dental Instruments Market Size, Dental Consumables And Dental Instruments Market Trends, Dental Consumables And Dental Instruments Market Growth, Dental Consumables And Dental Instruments Market Forecast, Dental Consumables And Dental Instruments Market Analysis

See original here:
Dental Consumables And Dental Instruments Market Size by Top Key Players, Growth Opportunities, Incremental Revenue , Outlook and Forecasts to 2026 -...

As the novel coronavirus swept through communities around the world, preying disproportionately on the poor and the vulnerable, one disadvantaged group has demonstrated a remarkable resistance. Women, whether from China, Italy or the U.S., have been less likely to become acutely ill and far more likely to survive.

Which has made doctors wonder: Could hormones produced in greater quantities by women be at work?

Now scientists on two coasts, acting quickly on their hunches in an effort to save mens lives, are testing the hypothesis. The two clinical trials will each dose men with the sex hormones for limited durations.

Last week, doctors on Long Island in New York started treating Covid-19 patients with estrogen in an effort to increase their immune systems, and next week, physicians in Los Angeles will start treating male patients with another hormone that is predominantly found in women, progesterone, which has anti-inflammatory properties and can potentially prevent harmful overreactions of the immune system.

Theres a striking difference between the number of men and women in the intensive care unit, and men are clearly doing worse, said Dr. Sara Ghandehari, a pulmonologist and intensive care physician at Cedars-Sinai in Los Angeles who is the principal investigator for the progesterone study. She said 75 percent of the hospitals intensive care patients and those on ventilators are men.

And pregnant women, who are usually immunocompromised but have high levels of estrogen and progesterone, tend to have mild courses of the disease. So something about being a woman is protective, and something about pregnancy is protective, and that makes us think about hormones, Dr. Ghandehari said.

Some experts who study sex differences in immunity, however, warned that hormones may fail to be the magic bullet that some are hoping for; even elderly women with Covid-19 are outliving their male peers, and there is a drastic reduction in levels of hormones for women after menopause.

The genesis of the estrogen trial at the Renaissance School of Medicine at Stony Brook University on Long Island stemmed from a similar observation, said Dr. Sharon Nachman, the trials principal investigator, who credited a Stony Brook surgeon, Dr. Antonios Gasparis, with the idea.

The trial enrolled its first patient this past week, and preliminary results could be available in a few months, she said.

Its totally out of the box, which is how good ideas often start, said Dr. Nachman, associate dean for research at the Renaissance School, which is part of the State University of New York.

The gender gap in coronavirus survival became apparent early in the pandemic. Reports from China indicated men were dying at higher rates, but the disparity was attributed to higher smoking rates. But the outcomes were consistent in other countries, with men in Italy dying at higher rates than women, and men in New York City dying at nearly double the rate of women.

Scientists who study sex differences say that both biological differences in immunity, as well as behavioral factors are at play. Men smoke more almost everywhere, they say; men also wash their hands less. While women appear to have more robust immune systems, these experts say, the causes are complex and multifactorial, and hormones are only part of the picture.

If such sex hormones were the primary protective factor for women, then elderly women with Covid-19 would fare as poorly as elderly men, because womens reproductive hormones plummet after menopause, said Sabra Klein, a scientist who studies sex differences in viral infections and vaccination responses at the Johns Hopkins Bloomberg School of Public Health.

But thats not the case, she said.

We see this bias across the life course, Dr. Klein said. Older men are still disproportionately affected, and that suggests to me its got to be something genetic, or something else, thats not just hormonal.

Estrogen has immune modulatory properties dont get me wrong, she continued. You could get a beneficial effect in both men and women. But if women are better at recovery at 93 years old, I doubt its hormones.

Research has shown estrogen may have an effect on a protein known as angiotensin-converting enzyme 2 (ACE2), for example. The coronavirus uses ACE2 receptors on the surfaces of cells as an entry route, and ACE2 is regulated differently in men and women, said Kathryn Sandberg, director of the Center for the Study of Sex Differences in Health, Aging and Disease at Georgetown University.

In studies with rats, Dr. Sandberg and her colleagues have shown that estrogen can reduce ACE2 protein expression in their kidneys, so it is possible the hormone may reduce ACE2 expression in men as well.

Dr. Nachman said, We may not understand exactly how estrogen works, but maybe we can see how the patient does, adding that estrogen plays a complex role, both in the early immune response that can help clear a viral infection, as well as in a secondary clean up or repair response, which can evolve into a cytokine storm.

While we see women do get infected, their responses are different, Dr. Nachman said. We see fewer of them having the second, disregulated immune response.

The Stony Brook estrogen trial is recruiting 110 patients who come to the hospitals emergency room with symptoms like fever, cough, shortness of breath or pneumonia, and who have either tested positive for Covid-19 or are presumed to have the illness, as long as they do not require intubation.

The trial is open to adult men as well as to women aged 55 and older, since they have low levels of estrogen. Half of the participants will be given an estradiol patch for one week, while the other half will serve as a control group, and researchers will follow them to see whether estrogen reduces the severity of their disease.

The Cedars-Sinai study is smaller, with only 40 subjects, all men, half of whom will be a control group. Only hospital inpatients with mild to moderate disease who have tested positive for Covid-19 can participate. (Patients with certain conditions, like a history of blood clots, are excluded for safety reasons.)

The patients will get two shots of progesterone a day for five days.

They will be monitored to see if their status is improving, how their needs for oxygen change and whether they go on to require intensive care or mechanical ventilation; their progress will be compared to patients in the control group.

The researchers in Los Angeles are pinning their hopes on progesterone rather than estrogen because research has shown that the hormone reduces pro-inflammatory immune cells, and supports those that fight inflammation, Dr. Ghandehari said. The hypothesis is that progesterone will prevent or dampen a harmful overreaction of the immune system, called a cytokine storm, and will reduce the likelihood of acute respiratory distress syndrome.

Both hormones are believed to be safe, especially when used for short durations. Participants will be warned of possible side effects that may be a first for many men, like tenderness in the breast and hot flashes.

See original here:
Can Estrogen and Other Sex Hormones Help Men Survive Covid-19? - The New York Times

WEDNESDAY, April 29, 2020 (HealthDay News) -- New research adds to a growing body of evidence that suggests men are far more vulnerable to severe COVID-19 than women are.

Although both genders fall ill in the same numbers, men are 2.5 times more likely to get severe disease and die, the study from China showed.

The finding comes as scientists in New York and California are starting to test a novel hypothesis that sex hormones might play a part in disease severity.

Last week, doctors on Long Island started treating COVID-19 patients with estrogen to boost their immune systems, The New York Times reported. And beginning next week, physicians in Los Angeles will start treating male patients with progesterone, a hormone that is predominantly found in women. Progesterone has anti-inflammatory properties and might prevent the immune system from overreacting, the researchers explained.

"There's a striking difference between the number of men and women in the intensive care unit, and men are clearly doing worse," Dr. Sara Ghandehari, a pulmonologist and intensive care physician at Cedars-Sinai in Los Angeles, told the Times. She is the principal investigator for the progesterone study.

But experts who study sex differences in immunity warned that hormones may not be the answer. Even elderly women with COVID-19 are outliving their male peers, despite drastic reductions in levels of hormones for women after menopause, they noted.

In the study from China, published April 29 in the journal Frontiers in Public Health, the differences between men and women showed up early in the coronavirus pandemic.

"Early in January, we noticed that the number of men dying from COVID-19 appeared to be higher than the number of women," explained researcher Dr. Jin-Kui Yang, a physician at Beijing Tongren Hospital.

"This raised a question: Are men more susceptible to getting or dying from COVID-19? We found that no one had measured gender differences in COVID-19 patients, and so began investigating," Yang said in a journal news release.

Included in the study were 43 patients treated by Yang's team, plus data on an additional 1,000 COVID-19 patients. The researchers also looked at the records of 524 SARS patients from 2003.

According to one large COVID-19 dataset, more than 70% of the patients who died were male, which meant that men had 2.5 times the death rate of women.

Being a man was also a risk factor for more severe illness, regardless of age.

Men who had SARS were also more likely to die, compared with women, Yang's team noted. Also, men had higher levels of the ACE2 protein involved in both sicknesses, which may be an explanation.

Although more research is needed, Yang recommended that "additional supportive care and prompt access to the intensive care unit may be necessary for older male patients."

More information

For more on COVID-19, see the U.S. Centers for Disease Control and Prevention.

SOURCES: Frontiers in Public Health, news release, April 29, 2020; The New York Times

Go here to read the rest:
COVID-19 Continues to Strike Men Harder Than Women - HealthDay

Provided by SF Gate

By Deepak Chopra, MD, FACP, Rudolph E. Tanzi, PhD, Michelle Williams, ScD, Ryan Castle, William C. Bushell, PhD, Kimberly Brouwer, PhD, and Paul J. Mills, PhD

Although COVID-19 is very easily transmitted from person to person, the risk of subsequent hospitalization and death primarily affects people who are already at risk because of old age, infirmity and/or chronic diseases such as cancer, diabetes, autoimmune illness, obesity, and heart disease. All of these chronic illnesses are associated with measurable low-grade inflammation in the body. The chronic low-grade inflammation that develops with advanced age has become known as inflammaging. Most people with chronic illness unknowingly have low-grade inflammation. Recent research points to a second finding: these same disorders are often accompanied by persistent low-grade anxiety and depression.

All of this as a background increases the danger for a person when acute illness strikes. In addition to the elderly and chronically ill, COVID-19 is causing acute respiratory illness and stroke sometimes leading to death in seemingly otherwise healthy younger individuals. The transition from SARS-CoV-2 infection to diagnosed COVID-19 is typically accompanied by a cytokine storm. Cytokines are proteins that are major drivers of inflammation, and their rapid increase, or "storm is one of the bodys immune responses to acute threat.

In addition, studies have connected pro-inflammatory cytokines to the stress response; they regulate well-known stress hormones such as ACTH and cortisol. Three major systems are involved: the immune system, the central nervous system and the endocrine hormone system.

In the face of these connections, we are coming forward to suggest that complementary practicesdeep breathing, yoga, and meditationcan play an important role during this pandemic. These practices have been confirmed by hundreds of scientific studies to bring down over-activity of the autonomic nervous system, calm the mind from anxiety, reduce the stress response, regularize heartbeat, and lower blood pressure. Together, all of these diverse benefits are associated with reducing the invisible presence of chronic low-grade inflammation, especially if added to good sleep, exercise, and proper diet.

We dont fully understand how the immune response, linked to stress and inflammation, can turn lethal. As a response to cuts, wounds, invading pathogens, and other threats, prior to antibody formation, the body first responds with inflammation as a normal yet crucial healing function. But it has long been known that inflammation is paradoxical. Acute inflammation can over-react, harming or even killing the patient. (Instances of strokes and heart attacks among young COVID-19 patients might be linked to micro-cytokine storms in the brain and heart.)

The threat from low-grade chronic inflammation was not discovered until recently but seems to be widespread. It is unaccompanied by the swelling, burning, and redness of the skin that marks acute inflammation and therefore goes undetected by the patient or physician. Preventing and addressing chronic low-grade inflammation and its significant adverse consequences are urgent issues, even more urgent during a pandemic. There seems to be every reason to make the public aware how deep breathing, meditation, yoga, and other healthy lifestyle practices can help during this crisis and long afterwards.

Deepak Chopra MD, FACP, Clinical Professor of Family Medicine and Public Health at the University of California, San Diego

Rudolph E. Tanzi, PhD, Kennedy Professor of Neurology at Harvard Medical School/MGH

Michelle Williams, SM, ScD, Dean of the Faculty, Harvard T.H. Chan School of Public Health

Kimberly Brouwer, PhD, Professor and Chief, Department of Family Medicine and Public Health, Division of Global Health, Infectious Diseases Epidemiology, at the University of California, San Diego

Ryan Castle, Executive Director of the Chopra Library

William C. Bushell, PhD, medical anthropologist and research director of the Chopra Library

Paul J. Mills, PhD, Professor and Chief, Department of Family Medicine and Public Health, at the University of California, San Diego

Read the original:
The Key to Handling Stress and COVID-19 - msnNOW

Campus News

The Chancellor Charles P. Norton Medal is UB's highest honor. Photo: Douglas Levere

UBNOW STAFF

Mary Wilson, wife of the late Buffalo Bills owner Ralph Wilson and a strong advocate of Western New York for the past 29 years, will be awarded the Chancellor Charles P. Norton Medal, UBs highest honor.

Jean Wactawski-Wende, SUNY Distinguished Professor of Epidemiology, dean of the School of Public Health and Health Professionals, and an internationally recognized researcher on womens health issues, will receive the UB Presidents Medal in recognition of extraordinary service to the university.

SUNY honorary doctorates are being presented to UB alumna Donnica L. Moore, president of the Sapphire Womens Health Group, and Richard A. Schatz, research director of cardiovascular interventions at the Scripps Heart, Lung and Vascular Center.

Wactawski-Wende will receive the Presidents Medal during the School of Public Health and Health Professions virtual commencement ceremony on May 16; the other award recipients will receive their honors at a later date.

The Chancellor Charles P. Norton Medal is presented annually in public recognition of a person who has, in Nortons words, performed some great thing which is identified with Buffalo a great civic or political act, a great book, a great work of art, a great scientific achievement or any other thing which, in itself, is truly great and ennobling, and which dignifies the performer and Buffalo in the eyes of the world.

Announcing this years Norton Medal recipient, Jeremy M. Jacobs, chair of the UB Council, said that Mary Wilson richly deserves the honor for her longstanding commitment to the region.

This year, we were absolutely unanimous in our decision to honor Mary Wilson, he said. In her leadership of the Wilson Foundation, Mary is making an enduring and unprecedented impact on Buffalo and all of Western New York, which will be felt for many generations to come. Her dedication and work align perfectly with the spirit of the Norton Medal.

Wilson has been devoted to Western New York since she first arrived in the area for the Bills home opener in 1990. She has spent many years developing her Western New York Girls in Sports program, which biannually brings more than 200 9- to 12-year-old girls together to take part in various sports taught by young athletes from local universities and sports clubs. The program, now ensured to run in perpetuity, is organized by the United Way of Buffalo and Erie County through an endowment from the Ralph C. Wilson Jr. Foundation, of which Wilson serves as one of four life trustees.

She has also supported organizations benefiting communities in Buffalo, Erie County and Southeast Michigan, among them Hospice of Western New York, WNY Womens Foundation, Food Bank of Western New York, Albright-Knox Art Gallery, Girl Scouts of Western New York, the SPCA serving Erie County, the Buffalo Philharmonic Orchestra, the Alzheimers Association Greater Michigan Chapter, The Helm (formerly Services for Older Citizens), the Detroit Symphony Orchestra, the Detroit Historical Society and the Detroit Institute of Arts, to name a few.

The UB Presidents Medal, first presented in 1990, recognizes outstanding scholarly or artistic achievements, humanitarian acts, contributions of time or treasure, exemplary leadership or any other major contribution to the development of the University at Buffalo and the quality of life in the UB community.

President Satish K. Tripathi described recipient Jean Wactawski-Wende as a world-renowned epidemiologist who has brought great prominence to UB through her scholarly pursuits and academic excellence in the area of womens health.

A dedicated member of our university community for more than 30 years, Dr. Wactawski-Wende has made seminal contributions that have significantly impacted health care practice and disease prevention for women in the U.S. and around the world, he said.

Thanks to her tremendous leadership, she has further elevated the reputation of UB. Our university community, along with the many communities we serve, have been profoundly enriched by Dr. Wactawski-Wendes scholarship, teaching and service, and it is an honor to present the Presidents Medal to such a truly deserving recipient.

Of particular note is Wactawski-Wendes leadership role in the Womens Health Initiative (WHI), the largest longitudinal study of womens health in the United States. In 1993, she was part of the team that spearheaded UBs successful bid to become one of the federally funded studys 16 original vanguard clinical centers. Since the inception of the WHI, UB has received more than $30 million in funding from the National Institutes of Health to investigate health issues impacting postmenopausal women.

Among the WHIs major discoveries was the groundbreaking finding that intake of combined estrogen plus progestin was associated with an increased risk of heart disease, stroke and invasive breast cancer. That research, on which Wactawski-Wende served as a co-principal investigator, changed the use of hormone therapy in older women worldwide, potentially saving countless lives.

Through UBs current $6.2 million award extension of the WHI, she has overseen the continuation of research into many diseases associated with aging, such as cardiovascular disease, cancer, osteoporosis, stroke and dementia. She is also administering new studies that focus on frailty and predictors of healthy aging.

For those of us who know and have worked closely with Dr. Wactawski-Wende, we readily recognize the magnitude and excellence of her contributions to academic medicine, said Michael E. Cain, vice president for health sciences and dean of the Jacobs School of Medicine and Biomedical Sciences at UB. She is an eminent and distinguished scholar and leader whose work, professional service, and stature in her discipline and research field are outstanding and continue to grow.

An internationally recognized womens health expert and advocate, Donnica L. Moore is president of Sapphire Womens Health Group, a multimedia firm that educates women about the benefits of a healthy lifestyle. A pioneering physician, Moore utilizes public speaking and multiple media platforms including her own website and podcast to share impactful health information in laypersons terms.

She will receive a SUNY Honorary Doctorate in Science.

Dr. Moores significant accomplishments associated with women's health set an inspiring example for our university community and reflect the values of both UB and the SUNY system, Tripathi said.

Breaking barriers to educate women about an array of health-related topics, she has demonstrated a sustained and dedicated commitment to the well-being of women around the globe. One of UBs most distinguished alumni, Dr. Moore in utilizing accessible platforms to create broad access to sound, peer-reviewed medical information is enhancing lives in communities near and far.

A 1986 alumna of the Jacobs School of Medicine and Biomedical Sciences, Moore underwent residency training in obstetrics and gynecology at Temple University, followed by a year of family medicine training at Memorial Hospital of Burlington, New Jersey. The editor-in-chief of Womens Health for Life, she has served on the editorial boards of the Journal of Women's Health and the Journal of the American Medical Womens Association, in addition to the board of directors of the Society for Womens Health Research, among other organizations.

Known for her relatable delivery and depth of expertise, Moore was the womens health contributor for NBCs Later Today and has appeared more than 800 times on such programs as The Oprah Winfrey Show, The Anderson Cooper Show and Good Morning America. Additionally, she has been a medical adviser or medical advisory board member for companies including DuPont and Helm Pharmaceuticals.

Richard A. Schatz is co-creator of the first coronary stent approved by the Food and Drug Administration for restenosis. Known as the Palmaz-Schatz stent, this life-saving device has been used to treat coronary artery disease in nearly 100 million patients worldwide since its approval in 1994. It is considered one of the top 10 medical device patents of the past 50 years.

He will receive a SUNY Honorary Doctorate in Science.

Dr. Schatz is widely known as the father of modern interventional cardiology for good reason, Tripathi said. Every day, his groundbreaking work is realized in operating rooms across the country and beyond. The stent he co-created spurred a revolution in the treatment of coronary artery disease and, 30 years later, it has had an immeasurable impact on health care.

By contributing to society through his biomedical innovations and inventions, Dr. Schatz has improved the lives of tens of millions of people while embodying the ideals of our university community and our university system.

A New York native, Schatz is the research director of cardiovascular interventions at the Scripps Clinic and director of gene and stem cell therapy. He is an elected fellow of the American College of Cardiology; in 2019, he received the Fritz J. And Dolores H. Russ Prize, which recognizes biomedical engineering achievements that have significantly improved the human condition. He is also the recipient of the Barton Haynes Lifetime Scholar Award from Duke University Medical Center.

Schatz attended UB in the early 1970s before gaining early admission to Duke Medical School, then completed his cardiology training at Brooke Army Medical Center. Throughout his career, he has maintained a strong affinity for UB, crediting the universitys faculty and curriculum for inspiring him to pursue a career in medicine.

Read more:
Wilson to receive Norton Medal - UB Now: News and views for UB faculty and staff - University at Buffalo Reporter

label.share.this_page

Facebook

Twitter

WhatsApp

Copy Link

URL copied

May 1, 2020

Find out more about the coronavirus pandemic.

By Dr. Jenifer Maynard

WHAT IS CORONAVIRUS and WHAT IS A PANDEMIC?

COVID-19 PRIMARILY SPREADS FROM PERSON TO PERSON AND FROM CONTAMINATED OBJECTS AND SURFACES

SYMPTOM RECOGNITION

DIAGNOSIS

TREATMENT

REDUCE YOUR RISK OF COVID-19! FOLLOW THESE GUIDELINES

THE IMMUNE SYSTEM

The immune system is complex, is composed of special organs, cells, and chemicals that prevent, limit and fight infection. The main components of the immune system include white blood cells, antibodies, the complement system, the lymphatic system, the spleen, the thymus, and bone marrow. Keep your immune system fighting fit with a comprehensive approach to all aspects of your health: physical, mental, emotional, and spiritual.

1. Dont smokea. Smoking decreases circulation and negatively affects lung function. Smoking is linked to many diseases, such as cancer, coronary artery disease, strokes, emphysema and other lung diseases. All of these reduce immune function.

2. Avoid excessive alcohola. Alcohol reduces immune system function by negatively affecting the digestive system, circulatory system, respiratory system, and decreases the production of immune cells.

3. Get adequate sleepa. Inadequate sleep may increase your risk of illness, including diabetes, obesity and heart disease. Most adults should aim for a minimum of 7 hours of sleep per night.

4. Minimize stressa. Cortisol is the hormone released during periods of high stress; it is known to suppress the immune system.b. To moderate your stress response, use relaxation techniques that are most effective for you - these can include yoga, meditation, prayer, listening to music, reading, walking, talking with a friend.c. Laughter is a great form of stress relief. It enhances oxygen uptake stimulating the heart and lungs and increases endorphins, thereby soothing tension and reducing stress.

5. Eat a diet high in fruits and vegetablesa. Recommended daily servings of fruit = 2+ (1 serve = 1 raw fruit, 1 cup of berries, or 1 cup of juice)b. Recommended daily servings of vegetables = 5+ (1 serve = 1 cup raw or cup cooked vegetables)c. Whole plant foods contain antioxidants, a substance that protects cells against the potentially damaging effects of free radicals. Antioxidant rich foods include blueberries, pecans, dark chocolate, strawberries, artichokes, goji berries, raspberries, kale, red cabbage, beans, beets, and spinach.

6. Encourage healthy gut floraa. 70% of our immune system is located within the gut. To encourage good gut bacteria, eat plenty of fibrous foods and pre-biotic foods such as, bananas, chicory, and flax seeds.b. Fruits and vegetables are excellent sources of fiber, helping to reduce constipation and improve gut microbiome.

7. Eat healthy fatsa. Healthy fats, like those found in avocados, olive oil, or salmon, may boost the bodys immune response to pathogens (bacteria and viruses) by decreasing inflammation.

8. Consume sugar sparinglya. Sugar significantly reduces the ability of white blood cells to destroy pathogens.

9. Exercise regularlya. Moderate exercise improves the immune system by stimulating the lymphatic system. The lymphatic system houses immune cells that kill off abnormal cells and harmful substances. Muscle contractions during exercise works as the pump for the lymphatic system, so that it flows more effectively and potentially prevents infections.b. Intense bursts of exercise and prolonged training should be avoided when you feel unwell as this can depress the immune system - reduce training if presenting with excessive fatigue.

10. Proper hygienea. Wash your hands regularly, the Center for Disease Control (CDC) recommends lathering with soap and scrubbing for 20 seconds.b. When you dont have access to soap and water, use an alcohol-based hand sanitizer (>60% alcohol)c. Decontaminate frequently touched surfaces by wiping down with disinfectant.

The contents of the Health site are for informational purposes only and should not be treated as medical, psychiatric, psychological, health care or health management advice. The materials herein are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this site. Reliance on any information provided herein is solely at your own risk.

A special thanks to the author, Dr Jenifer Maynard, WTA Medical Advisor.

Original post:
Physically Speaking: The facts about COVID-19 - WTA Tennis

During the rare moments youve ventured outside these days, youve probably noticed clearer skies and the benefits of reductions in air pollution.

Long-term exposure to air pollution increases the danger associated with four of the biggest Covid-19 mortality risks: diabetes, hypertension, coronary artery disease and asthma. It also can make the immune system overreact, exaggerating the inflammatory response to common pathogens.

But there are other common contaminants in our homes that are also likely to be hacking our immune systems, which have had less attention.

Youve probably heard about synthetic chemicals in non-stick pans, cosmetics and aluminum cans disrupting our hormones. The notion of endocrine-disrupting chemicals was only widely accepted about a decade ago, when scientific societies raised the alarm. The science of immune disruption is even newer, with a large review in a major scientific journal just out last year.

You may have heard of forever chemicals, or perfluoroalkylsubstances (PFAS) from the movie Dark Waters, with Mark Ruffalo. These chemicals, used to keep food from sticking to surfaces and our clothing free of oily stains, are widely found in the US water supply. Were talking about chemicals that 110 million Americans drink each day that increase the death rate of mice exposed to influenza type A. Children exposed during pregnancy have worse immune responses to vaccines, with weaker antibody responses. Studies in Norway, Sweden and Japan have found greater difficulties in children with various infections, ranging from colds to stomach bugs to ear infections.

Bisphenol A, or BPA, which is found in thermal paper receipts and aluminum can linings, has been found in the laboratory to increase the bodys release of a molecule called interleukin-6, or IL-6, that may be involved in the raging wildfire inside the lung that has already killed so many from coronaviruses. One of the more promising treatments for coronavirus patients is tocilizumab, an antibody to IL-6. Phthalates, used in cosmetics, personal care products and food packaging, alter levels of cytokines, which are key players in the immune response to coronavirus.

Is the evidence perfect? Hardly. And we have to rely on observational studies you cant run a randomized controlled trial of potentially toxic mixtures of virus and chemical exposures. There are ethical and logistical challenges to running these kinds of studies. But absence of evidence doesnt mean absence of harm.

Will preventing these exposures now change exposure to the novel coronavirus? No. Stay home, wash your hands with soap and water at least 30 seconds at a time, and keep your social distancing game strong. Right now, we need to keep as calm as we can and carry on as best we can. Weve overcome other disasters 9/11, Katrina and Sandy, to name just a few. And once we return to normal, we can limit these exposures in our daily lives using cast iron and stainless steel instead of nonstick pans, avoiding canned food consumption, and reducing the use of plastic in our lives.

But when we return to normal, we have to ask ourselves how and why we got here, just like we did for those disasters. West Nile, Zika, dengue, Ebola and other infections are on the rise, and they are attacking us when our immune defenses are being attacked by preventable contaminants in the environment. Government and industry have dragged their feet time and again to limit these exposures because of intense economic pressure. Youve probably heard that the US Environmental Protection Agency (EPA) has used the coronavirus pandemic to waive its enforcement rules, allowing companies to pollute without consequences.

But its not just at the EPA where science has undermined human health over chemicals that can affect the immune system. The Food and Drug Administration (FDA) has failed to protect kids from known hazards in food packaging and other contact surfaces, allowing industry to vouch for safety without careful study of potential adverse effects. And when negative effects are found, the FDA is limited in its ability to require companies to stop using toxic ingredients in its materials.

Infections are not just something we vaccinate away or treat. New infections will emerge even more in the future if we dont appreciate the consequences of messing with Mother Nature and realize our immune systems are being hacked, too.

Leonardo Trasande is Jim G Hendrick MD professor of pediatrics at NYU Grossman school of medicine, and the author of Sicker, Fatter, Poorer, which describes the effects of endocrine-disrupting chemicals on human health and the economy and what we can do about it. Akhgar Ghassabian is a physician-epidemiologist in the department of pediatrics at NYU Grossman, where she studies the effects of synthetic chemicals on immune function and childrens health

More:
The toxic chemicals in our homes could increase Covid-19 threat - The Guardian

After Rehema was pressured to abort and began a chemical abortion, she reached out and received help from the Abortion Pill Rescue Network in Nairobi, Kenya, and was able to save her unborn son through Abortion Pill Reversal (APR).

Taken by her mother to no less than three abortion facilities, having witnessed the callousness toward life present in the abortion industry, and facing losing a place to live because of her conviction to try to save her unborn son, she is thankful for his life and hopeful for the future.

God has a purpose for my life in this boy, she said. So definitely He will make a way.

And trust me, Rehema stated. (Chemical) abortion can be reversed. I am a living testimony.

Tweet This: And trust me, (chemical) abortion can be reversed. I am a living testimony.

Rehema also said it was God who brought her to Heartbeat Internationals Abortion Pill Rescue Network (APRN). She acted quickly, the reversal has been successful, and she wanted to share her experience.

[Click here to subscribe to Pregnancy Help News!]

Hers is the latest story of a woman falsely made to feel like she had no other choice but to abort.

It is also the story of yet another life saved through the APRN, which consists of more than 600 health care professionals prepared to administer an FDA-approved drug that has successfully stopped abortions after a mother requests intervention. Along with the 600-plus health care practitioners, some 300 pregnancy help organizations in the APRN network also assist women who choose to try and save their baby by initiating the Abortion Pill Reversal (APR) process.

The abortion pill, also known as medication abortion, chemical abortion, RU-486 or self-managed abortion, refers to the drugs mifepristone and misoprostol, taken to abortion a child within the first 10 weeks of a pregnancy.

That first pill, mifepristone, blocks the effects of progesterone the natural hormone that women produce which provides the essential nutrients needed for their developing baby to thrive. The second drug in the chemical abortion process, misoprostol, is taken 6-48 hours later, typically at home, causing cramping and bleeding associated with emptying the mothers uterus, when she then delivers her deceased child.

A chemical abortion can be reversed after taking mifepristone and before misoprostol.

APR works by giving the mother extra progesterone up to 72 hours after she takes the first chemical abortion drug. The treatment has the best chance for success when started within 24 hours. APR is a new application of an FDA-approved progesterone treatment used beginning in the 1950s to stop miscarriages. To date, more than 900 lives have been saved through APR.

The APRN continues to expand internationally, and the month of March saw a record number of moms beginning the abortion pill reversal process through the Network.

Rehema shared her story with Heartbeat National after confirming that her unborn son was healthy following initiation of the APR regimen.

She had gotten a call from her mother on April 21, telling her she would be taking her for an abortion, the reason being that Rehema and the babys father are of different faiths.

They went to a Marie Stopes abortion facility where after an ultrasound Rehema was told she 22 weeks and 4 days pregnant. With their standard cut-off for conducting abortions at 20 weeks, Rehema said the facility declined to do the procedure.

But her mother didnt relax, she said, taking her to another local Marie Stopes location, where they also declined to conduct the abortion.

Rehemas mother took her to another abortionist who regardless of her childs gestational age agreed to perform the abortion.

Asking the abortionist what would happen if her baby survived the procedure and was born - and crying - she said he indicated in no uncertain terms that he knows how tosilencesuch children, which disturbed her.

I got goosebumps all over, she said. I told him to give me time to think.

Rehema said she went home, but her mother was just too persistent, kept mocking her, and so on April 25 she decided to visit one of the abortion contacts her mother had found.

And they gave me mifepristone and told me to swallow it immediately, Rehema said, immediately sorry for the decision.

I was desperate, she continued. I didnt know who to talk to on the night of the 25th I cried a lot.

I was feeling guilty, she said. How could I kill my innocent little one? I just saw how healthy he was during the ultrasound

I was losing it, Rehema told Heartbeat International. Then I decided to go through Google

God directed me to APR, said Rehema. And I sent an email.

Tweet This: God directed me to Abortion Pill Reversal

In no time I got a How may I help you? she recounted.

Rehema talked to several APRN consultants, whom she said have been calling, texting and emailing her, as well as checking in with her over social media.

May God bless you all, she said of the consultants.

Rehema was connected with a doctor in the APRN who began the APR protocol.

This one is just an angel in human flesh, she stated of the physician.

The doctors office worked with her financially on treatment, she said, even though she did not have much money, and everyone at the clinic where she has been receiving treatment has been friendly.

I am assured everything is fine, no complications at all, Rehema told Heartbeat.

And guess what guys ware having a healthy baby boy!!

Isnt our God a wonderful God she exclaimed. Isnt He the most merciful and most forgiving?

Rehema then came home and found her mother waiting.

She said her mother told her that since she didnt want to abort, that she should know she is in this alone, and to leave her place.

Despite this Rehema has remained hopeful and happy to have her son.

She said she just wants to have a new start.

I have seen the worst, but I conquered, Rehema told Heartbeat. Much love and God Bless!!

Tweet This: I have seen the worst, but I conquered. Much love and God Bless!! Mom whose baby was saved with APR

The APRNs consultants remain in contact with Rehema. Pregnancy Help News and Heartbeat International will monitor her situation and publish updates when possible.

Editors note: Heartbeat International manages the Abortion Pill Rescue Network and Pregnancy Help News.

Read the original:
I have seen the worst, but I conquered - mom pressured to abort looks forward with hope after baby saved with APR - Pregnancy Help News

TEL AVIV, Israel & PARSIPPANY, N.J. & INCHEON, South Korea--(BUSINESS WIRE)-- Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Celltrion Healthcare, Co., Ltd. (KRX KOSDAQ:091990), today announced that TRUXIMA (rituximab-abbs) injection is now available in the United States for the treatment of:

TRUXIMA is the only biosimilar to the reference product Rituxan1 (rituximab) available to treat rheumatoid arthritis in the United States. See important safety information below including Boxed Warning regarding fatal infusion-related reactions, severe mucocutaneous reactions, hepatitis B virus reactivation and progressive multifocal leukoencephalopathy.

We are proud to make TRUXIMA available to patients and providers as a treatment option for these indications, especially as this is the only rituximab biosimilar indicated for rheumatoid arthritis, said Brendan OGrady, Executive Vice President, North America Commercial, Teva. Following the launch of our other biosimilar earlier this year, we remain focused on our commitment to lower healthcare costs and increase price competition through the availability of biosimilars.

Celltrion Healthcare and Teva Pharmaceutical Industries Ltd. entered into an exclusive partnership in October 2016 for Teva to commercialize TRUXIMA in the U.S. and Canada. In May 2019, TRUXIMA was approved by the U.S. Food and Drug Administration (FDA) to match all of the reference products oncology indications described below.

We are pleased that patients in the United States can now have access to TRUXIMA for these new indications, said Mr. Hyoung-Ki Kim, Vice Chairman at Celltrion Healthcare. We believe that the continued use of biosimilars in the U.S. market will contribute to addressing unmet needs for patients and providers.

Earlier this year, the Centers for Medicare and Medicaid Services (CMS) granted pass-through status for TRUXIMA in the hospital outpatient setting. The Wholesale Acquisition Cost (WAC or list price) for TRUXIMA will be 10 percent lower than the reference product. TRUXIMA is expected to be available through primary wholesalers at a WAC of $845.55 per 100mg vial and $4,227.75 per 500mg vial. Actual costs to individual patients and providers for TRUXIMA are anticipated to be lower than WAC because WAC does not account for additional rebates and discounts that may apply. Savings on out-of-pocket costs may vary depending on the patients insurance payer and eligibility for participation in the assistance program.

Teva also offers dedicated patient support services through the CORE program. CORE is available to help eligible patients, caregivers and healthcare professionals navigate the reimbursement process. CORE offers a range of services, including benefits verification and coverage determination, support for precertification and prior authorization, assistance with coverage guidelines and claims investigation, and support through the claims and appeals process. A savings program is also available for eligible commercially insured patients. To learn more, please visit TevaCORE.com.

Please see the Important Safety Information below including the Boxed Warning regarding fatal infusion-related reactions, severe mucocutaneous reactions, hepatitis B virus reactivation and progressive multifocal leukoencephalopathy. For more information, please see the full prescribing information.

Indications TRUXIMA (rituximab-abbs) is indicated for the treatment of adult patients with:

Non-Hodgkins Lymphoma (NHL)

Chronic Lymphocytic Leukemia (CLL)

Rheumatoid Arthritis (RA)

Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)

Important Safety Information

WARNING: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

Infusion-Related Reactions: Administration of rituximab products, including TRUXIMA, can result in serious, including fatal, infusion-related reactions. Deaths within 24 hours of rituximab infusion have occurred. Approximately 80% of fatal infusion-related reactions occurred in association with the first infusion. Monitor patients closely. Discontinue TRUXIMA infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion-related reactions

Severe Mucocutaneous Reactions: Severe, including fatal, mucocutaneous reactions can occur in patients receiving rituximab products

Hepatitis B Virus (HBV) Reactivation: HBV reactivation can occur in patients treated with rituximab products, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with TRUXIMA. Discontinue TRUXIMA and concomitant medications in the event of HBV reactivation

Progressive Multifocal Leukoencephalopathy (PML), including fatal PML, can occur in patients receiving rituximab products

WARNINGS AND PRECAUTIONS

Infusion-Related Reactions - Rituximab products can cause severe, including fatal, infusion-related reactions. Severe reactions typically occurred during the first infusion with time to onset of 30-120 minutes. Rituximab product-induced infusion-related reactions and sequelae include urticaria, hypotension, angioedema, hypoxia, bronchospasm, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, cardiogenic shock, anaphylactoid events, or death

Premedicate patients with an antihistamine and acetaminophen prior to dosing. For RA, GPA, and MPA patients, methylprednisolone 100 mg intravenously or its equivalent is recommended 30 minutes prior to each infusion. Institute medical management (e.g. glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. Depending on the severity of the infusion-related reaction and the required interventions, temporarily or permanently discontinue TRUXIMA. Resume infusion at a minimum 50% reduction in rate after symptoms have resolved. Closely monitor the following patients: those with pre-existing cardiac or pulmonary conditions, those who experienced prior cardiopulmonary adverse reactions, and those with high numbers of circulating malignant cells (25,000/mm3)

Severe Mucocutaneous Reactions - Mucocutaneous reactions, some with fatal outcome, can occur in patients treated with rituximab products. These reactions include paraneoplastic pemphigus, Stevens-Johnson syndrome, lichenoid dermatitis, vesiculobullous dermatitis, and toxic epidermal necrolysis. The onset of these reactions has been variable and includes reports with onset on the first day of rituximab exposure. Discontinue TRUXIMA in patients who experience a severe mucocutaneous reaction. The safety of re-administration of rituximab products to patients with severe mucocutaneous reactions has not been determined

Hepatitis B Virus Reactivation - Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death, can occur in patients treated with drugs classified as CD20-directed cytolytic antibodies, including rituximab products. Cases have been reported in patients who are hepatitis B surface antigen (HBsAg) positive and also in patients who are HBsAg negative but are hepatitis B core antibody (anti-HBc) positive. Reactivation also has occurred in patients who appear to have resolved hepatitis B infection (i.e., HBsAg negative, anti-HBc positive and hepatitis B surface antibody [anti-HBs] positive)

HBV reactivation is defined as an abrupt increase in HBV replication manifesting as a rapid increase in serum HBV DNA levels or detection of HBsAg in a person who was previously HBsAg negative and anti-HBc positive. Reactivation of HBV replication is often followed by hepatitis, i.e., increase in transaminase levels. In severe cases increase in bilirubin levels, liver failure, and death can occur

Screen all patients for HBV infection by measuring HBsAg and anti-HBc before initiating treatment with TRUXIMA. For patients who show evidence of prior hepatitis B infection (HBsAg positive [regardless of antibody status] or HBsAg negative but anti-HBc positive), consult with physicians with expertise in managing hepatitis B regarding monitoring and consideration for HBV antiviral therapy before and/or during TRUXIMA treatment

Monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following TRUXIMA therapy. HBV reactivation has been reported up to 24 months following completion of rituximab therapy

In patients who develop reactivation of HBV while on TRUXIMA, immediately discontinue TRUXIMA and any concomitant chemotherapy, and institute appropriate treatment. Insufficient data exist regarding the safety of resuming TRUXIMA treatment in patients who develop HBV reactivation. Resumption of TRUXIMA treatment in patients whose HBV reactivation resolves should be discussed with physicians with expertise in managing HBV

Progressive Multifocal Leukoencephalopathy (PML) - JC virus infection resulting in PML and death can occur in rituximab product-treated patients with hematologic malignancies. The majority of patients with hematologic malignancies diagnosed with PML received rituximab in combination with chemotherapy or as part of a hematopoietic stem cell transplant. Most cases of PML were diagnosed within 12 months of their last infusion of rituximab

Consider the diagnosis of PML in any patient presenting with new-onset neurologic manifestations. Evaluation of PML includes, but is not limited to, consultation with a neurologist, brain MRI, and lumbar puncture

Discontinue TRUXIMA and consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML

Tumor Lysis Syndrome (TLS) - Acute renal failure, hyperkalemia, hypocalcemia, hyperuricemia, or hyperphosphatemia from tumor lysis, sometimes fatal, can occur within 12-24 hours after the first infusion of rituximab products in patients with NHL. A high number of circulating malignant cells ( 25,000/mm3) or high tumor burden, confers a greater risk of TLS

Administer aggressive intravenous hydration and anti-hyperuricemic therapy in patients at high risk for TLS. Correct electrolyte abnormalities, monitor renal function and fluid balance, and administer supportive care, including dialysis as indicated

Infections - Serious, including fatal, bacterial, fungal, and new or reactivated viral infections can occur during and following the completion of rituximab product-based therapy. Infections have been reported in some patients with prolonged hypogammaglobulinemia (defined as hypogammaglobulinemia >11 months after rituximab exposure). New or reactivated viral infections included cytomegalovirus, herpes simplex virus, parvovirus B19, varicella zoster virus, West Nile virus, and hepatitis B and C. Discontinue TRUXIMA for serious infections and institute appropriate anti-infective therapy. TRUXIMA is not recommended for use in patients with severe, active infections

Cardiovascular Adverse Reactions - Cardiac adverse reactions, including ventricular fibrillation, myocardial infarction, and cardiogenic shock may occur in patients receiving rituximab products. Discontinue infusions for serious or life-threatening cardiac arrhythmias. Perform cardiac monitoring during and after all infusions of TRUXIMA for patients who develop clinically significant arrhythmias, or who have a history of arrhythmia or angina

Renal Toxicity - Severe, including fatal, renal toxicity can occur after rituximab product administration in patients with NHL. Renal toxicity has occurred in patients who experience tumor lysis syndrome and in patients with NHL administered concomitant cisplatin therapy during clinical trials. The combination of cisplatin and TRUXIMA is not an approved treatment regimen. Monitor closely for signs of renal failure and discontinue TRUXIMA in patients with a rising serum creatinine or oliguria

Bowel Obstruction and Perforation - Abdominal pain, bowel obstruction and perforation, in some cases leading to death, can occur in patients receiving rituximab in combination with chemotherapy. In postmarketing reports, the mean time to documented gastrointestinal perforation was 6 (range 1-77) days in patients with NHL. Evaluate if symptoms of obstruction such as abdominal pain or repeated vomiting occur

Immunization - The safety of immunization with live viral vaccines following rituximab product therapy has not been studied and vaccination with live virus vaccines is not recommended before or during treatment

Prior to initiating TRUXIMA physicians should ensure patients vaccinations and immunizations are up-to-date with guidelines. Administration of any non-live vaccines should occur at least 4 weeks prior to a course of TRUXIMA

Embryo-Fetal Toxicity - Based on human data, rituximab products can cause fetal harm due to B-cell lymphocytopenia in infants exposed to rituximab in-utero. Advise pregnant women of the risk to a fetus. Females of childbearing potential should use effective contraception while receiving TRUXIMA and for 12 months following the last dose of TRUXIMA

Concomitant Use With Other Biologic Agents and DMARDS Other Than Methotrexate

Observe patients closely for signs of infection if biologic agents and/or DMARDs are used concomitantly as limited safety data is available.

Use of concomitant immunosuppressants other than corticosteroids has not been studied in GPA or MPA patients exhibiting peripheral B-cell depletion following treatment with rituximab products

Use in RA Patients Who Have Not Had Prior Inadequate Response to TNF Antagonists

TRUXIMA should only be used in patients who have had a prior inadequate response to one or more TNF antagonist

Most common adverse reactions in clinical trials of NHL (25%) were: infusion-related reactions, fever, lymphopenia, chills, infection, and asthenia

Most common adverse reactions in clinical trials of CLL (25%) were: infusion-related reactions and neutropenia

Most common adverse reactions in clinical trials of RA (10%) were: upper respiratory tract infection, nasopharyngitis, urinary tract infection, and bronchitis (other important adverse reactions include infusion-related reactions, serious infections, and cardiovascular events)

Most common adverse reactions in clinical trials of GPA and MPA (15%) were: infections, nausea, diarrhea, headache, muscle spasms, anemia, peripheral edema, and infusion-related reactions

Nursing Mothers - There are no data on the presence of rituximab in human milk, the effect on the breastfed child, or the effect on milk production. Since many drugs including antibodies are present in human milk, advise a lactating woman not to breastfeed during treatment and for at least 6 months after the last dose of TRUXIMA due to the potential for serious adverse reactions in breastfed infants

About TRUXIMA TRUXIMA (rituximab-abbs) is a U.S. Food and Drug Administration (FDA)-approved biosimilar to RITUXAN (rituximab) for the treatment of: adult patients with CD20-positive, B-cell NHL to be used as a single agent or in combination with chemotherapy or CLL in combination with fludarabine and cyclophosphamide (FC); for rheumatoid arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies; and granulomatosis with polyangiitis (GPA) (Wegeners Granulomatosis) and microscopic polyangiitis (MPA) in adult patients in combination with glucocorticoids

TRUXIMA has the same mechanism of action as Rituxan and has demonstrated biosimilarity to Rituxan through a totality of evidence.

About Celltrion Healthcare, Co. Ltd. Celltrion Healthcare conducts the worldwide marketing, sales and distribution of biological medicines developed by Celltrion, Inc. through an extensive global network that spans more than 120 different countries. Celltrion Healthcares products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US Food and Drug Administration (FDA) cGMP guidelines and the EU GMP guidelines.

About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve peoples lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at http://www.tevapharm.com.

Teva's Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the launch of TRUXIMA Injection for Rheumatoid Arthritis in the United States, which are based on managements current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2019, including in the sections captioned "Risk Factors and Forward Looking Statements. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

1 RITUXAN is a registered trademark of Genentech and Biogen.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200504005064/en/

Here is the original post:
Teva and Celltrion Healthcare Announce the Launch of TRUXIMA (rituximab-abbs) Injection for Rheumatoid Arthritis, the Only Biosimilar to Rituxan...

Many cultures use the fruit and its juices as a traditional folk remedy to treat or prevent various ailments.

Modern research has linked pineapple juice and its compounds to health benefits, such as improved digestion and heart health, reduced inflammation, and perhaps even some protection against cancer. However, not all evidence has been conclusive.

Here are 7 science-based benefits of pineapple juice, based on the current research.

1. Rich in Nutrients

Pineapple juice provides a concentrated dose of various nutrients. One cup (240 mL) contains around:

• Calories: 132
• Protein: less than 1 gram
• Fat: less than 1 gram
• Carbs: 33 grams
• Sugars: 25 grams
• Fiber: less than 1 gram
• Manganese: 55% of the Daily Value (DV)
• Copper: 19% of the DV
• Vitamin B6: 15% of the DV
• Vitamin C: 14% of the DV
• Thiamine: 12% of the DV
• Folate: 11% of the DV
• Potassium: 7% of the DV
• Magnesium: 7% of the DV

Pineapple juice is particularly rich in manganese, copper, and vitamins B6 and C. These nutrients play an important role in bone health, immunity, wound healing, energy production, and tissue synthesis.

It also contains trace amounts of iron, calcium, phosphorus, zinc, choline, and vitamin K, as well as various B vitamins.

Summary

Pineapple juice is rich in a variety of vitamins and minerals. It's especially packed with manganese, copper, vitamin B6, and vitamin C all of which play important roles in the proper functioning of your body.

2. Contains Additional Beneficial Compounds

In addition to being rich in vitamins and minerals, pineapple juice is a good source of antioxidants, which are beneficial plant compounds that help keep your body healthy.

Antioxidants help neutralize unstable compounds known as free radicals, which can build up in your body due to factors like pollution, stress, or an unhealthy diet and cause cell damage.

Experts believe that the antioxidants in pineapple juice, particularly vitamin C, beta carotene, and various flavonoids, are in large part to thank for its potential beneficial effects.

Pineapple juice also contains bromelain, a group of enzymes linked to health benefits, such as reduced inflammation, improved digestion, and stronger immunity.

Summary

Pineapple juice is rich in antioxidants, which help protect your body from damage and disease. It also contains bromelain, a group of enzymes that may reduce inflammation, improve digestion, and boost immunity.

3. May Suppress Inflammation

Pineapple juice may help reduce inflammation, which is believed to be the root cause of many chronic diseases.

This may largely be due to its bromelain content. Some research suggests that this compound may be as effective as non-steroidal anti-inflammatory drugs (NSAIDs) but with fewer side effects.

In Europe, bromelain is approved for use to reduce inflammation caused by trauma or surgery, as well as to treat surgical wounds or deep burns.

In addition, there's evidence that ingesting bromelain before surgery may help reduce the level of inflammation and pain caused by surgery.

Some studies further suggest that bromelain may help reduce pain and inflammation caused by a sports injury, rheumatoid arthritis, or osteoarthritis of the knee.

That said, research has yet to test the direct effects of pineapple juice on inflammation.

Therefore, it's unclear whether the bromelain intakes achieved through drinking small to moderate amounts of pineapple juice would provide the same anti-inflammatory benefits as those observed in these studies.

Summary

Pineapple juice contains bromelain, a group of enzymes that may help reduce inflammation caused by trauma, injuries, surgery, rheumatoid arthritis, or osteoarthritis. However, more juice-specific studies are needed.

4. May Boost Your Immunity

Pineapple juice may contribute to a stronger immune system.

Test-tube studies suggest that bromelain, a mixture of enzymes naturally found in pineapple juice, may activate the immune system.

Bromelain may also improve recovery from infections, such as pneumonia, sinusitis, and bronchitis, especially when used in combination with antibiotics.

However, most of these studies are dated, and none have examined the immunity-boosting effects of pineapple juice in humans. Therefore, more research is needed to confirm these results.

Summary

Some research suggests that pineapple juice may contribute to a stronger immune system. It may also help increase the effectiveness of antibiotics. However, more studies are needed before strong conclusions can be made.

5. May Help Your Digestion

The enzymes in pineapple juice function as proteases. Proteases help break down protein into smaller subunits, such as amino acids and small peptides, which can then be more easily absorbed in your gut.

Bromelain, a group of enzymes in pineapple juice, may particularly help improve digestion in people whose pancreas cannot make enough digestive enzymes a medical condition known as pancreatic insufficiency.

Animal research suggests that bromelain may also help protect your gut from harmful, diarrhea-causing bacteria, such as E. coli and V. cholera.

Moreover, according to some test-tube research, bromelain may help reduce gut inflammation in people with inflammatory bowel disorders, such as Crohn's disease or ulcerative colitis.

That said, most studies have investigated the effect of concentrated doses of bromelain, rather than that of pineapple juice, and very few were conducted in humans. Therefore, more research is needed.

Summary

The bromelain in pineapple juice may aid digestion, guard against harmful, diarrhea-causing bacteria, and reduce inflammation in people with inflammatory bowel disorders. However, more research is needed.

6. May Promote Heart Health

The bromelain naturally found in pineapple juice may also benefit your heart.

Test-tube and animal studies suggest that bromelain may help reduce high blood pressure, prevent the formation of blood clots, and minimize the severity of angina pectoris and transient ischemic attacks two health conditions caused by heart disease.

However, the number of studies is limited, and none are specific to pineapple juice. Therefore, more research is needed before strong conclusions can be made.

Summary

Some research links the bromelain naturally found in pineapple juice to markers of improved heart health. However, more pineapple-juice-specific studies are needed.

7. May Help Fight Certain Types of Cancer

Pineapple juice may have potential cancer-fighting effects. Again, this is likely in large part due to its bromelain content.

Some studies suggest that bromelain may help prevent the formation of tumors, reduce their size, or even cause the death of cancerous cells.

However, these were test-tube studies using concentrated amounts of bromelain that were much higher than those you'd ingest from drinking a glass of pineapple juice. This makes it difficult to project their results to humans.

Therefore, more research is needed before strong conclusions can be made.

Summary

Test-tube studies suggest that concentrated amounts of bromelain may help protect against cancer. However, it's currently unclear whether pineapple juice offers similar benefits in humans.

Possible Precautions

Pineapple juice is generally considered safe for most people.

That said, bromelain, a group of enzymes naturally found in pineapple juice, may enhance the absorption of certain drugs, especially antibiotics and blood thinners.

As such, if you are taking medications, consult your physician or registered dietitian to make sure it's safe to consume pineapple juice.

This beverage's acidity may also trigger heartburn or reflux in some people. Specifically, those with gastroesophageal reflux disease (GERD) may want to avoid consuming large amounts of this beverage.

Despite its potential benefits, it's important to remember that pineapple juice remains low in fiber yet high in sugar.

This means it's unlikely to fill you up as much as eating the same quantity of raw pineapple would. Therefore, it may promote weight gain in some people.

What's more, while drinking small amounts of juice has been linked to a lower risk of type 2 diabetes and heart disease, drinking more than 5 ounces (150 mL) per day may have the opposite effect.

Therefore, it's likely best to avoid drinking too much pineapple juice, and when you do, stick to 100% pure varieties that are free of added sugars.

Summary

Pineapple juice is low in fiber yet rich in sugar, and drinking too much may lead to weight gain or disease. This beverage may also interact with medications and trigger heartburn or reflux in some people.

The Bottom Line

Pineapple juice contains a variety of vitamins, minerals, and beneficial plant compounds that may protect you from disease.

Studies link this beverage to improved digestion, heart health, and immunity. Pineapple juice or its compounds may also help reduce inflammation and perhaps even offer some protection against certain types of cancer.

However, human studies are limited, and it's unclear whether the effects observed in test tubes or animals can be achieved by small daily intakes of pineapple juice.

Moreover, this beverage remains low in fiber and rich in sugar, so drinking large quantities each day is not recommended.

From Your Site Articles

Related Articles Around the Web

See more here:
Why COVID-19 Is Hitting Men Harder Than Women - EcoWatch

The Judges of Yolo County Superior Court prior to Dan Wolks appointment

Even before this week, Yolo Countys bench seemed out of step with the rest of the state. For the last 13 years, according to various media sources, Californias bench has become more diversemore women, more people of color. Not Yolo County.

Yolo County is moving in the opposite direction with 8 white men and two women, one of whom is Latina. That was before Tuesday when Governor Newsom made what appears to be the latest appointment based on political connections.

Dan Wolk as you know is the former Mayor of Davis, having served from 2014 to 2016. In both 2014 and 2016, he ran for State Assembly and lost, first to Bill Dodd and then to Cecilia Aguiar-Curry. His professional experience is a little over a decade working for the Solano County Counsels office.

He has limited trial experience and his chief qualifications appear to be the fact that his mother is a retired State Senator and his father is a retired Dean of the UC Davis Law School.

Dan Wolk appears to be the latest Yolo County appointment that is based more on who someone is than their qualifications to be judge. Thats not fair to Dan Wolk and this issue did not begin with Governor Gavin Newsomit is a trend.

And it is a problem for the diversity on the Yolo County bench, which now has 9 white men in a county where whites only make up 46 percent of the total population, according to 2019 census estimates.

Indeed, if you look at Governor Newsoms judicial appointments overall on Tuesday, people wanting diversity would applaud them.

In March of 2019 after Governor Jerry Brown stepped down, a survey found that for the 13th straight year, Californias judicial bench has grown more diverse, according to new data released by the Judicial Council.

Governor Browns appointments, including the nearly 200 appointments made in his final year in office: women accounted for more than half of those appointees, and 41 percent identified as non-white.

Governor Newsom continued that trend as last year, his first, he appointed a majority of women and nonwhites to the bench.

That continued on Tuesday.Governor Newsom appointed 14 people to the bench8 women and just two white males.

So why is Yolo County different than other counties?

A big part has to do with its location, roughly 15 minutes from the State Capitol on the other side of the Sacramento River.

It is a small county, but it is prominentthe home of UC Davis, a major law school and academic center. Davis also happens to be the home of a number of State Capitol employees and staffers.

The problem here is actually very clear, and it goes back to the last six governor appointments to the bench starting in 2008.

In 2008, Governor Arnold Schwarzenegger appointed employment lawyer Samuel McAdam.In 2010, he appointed Dan Maguire, who was his deputy legal affairs secretary.

In 2012, Janene Beronio, one of the two women on the bench, was elected when retiring Judge Stephen Mock stepped down at the end of his term.

In 2015, Governor Brown appointed Sonia Corts, the first Latina to be judge in Yolo County.

In 2018, he appointed Tom Dyer and Peter Williams, both of whom were attorneys in his administration.

Now, in 2020, Governor Newsom appoints Dan Wolk, the former Mayor of Davis and the son of State Senator Lois Wolk.

While the 2018 appointees did not live in Yolo County, Sam McAdam, Dan Maguire, and Dan Wolk all live in Davis and Sonia Corts lived in Woodland.

A key question is why has Yolo County become the place where governors stick their legal counsel when they wish to award them with appointments?

Clearly, being near the capital is to Yolo Countys detriment. Clearly Yolo County lacks a deep bar association that is diverse. But we also know for a fact that there were very qualified women and women of color who have put their hats in the ring and got passed over in the last three appointments.

Is no one at the governors office paying attention to the bench in Yolo for ethnic make up?

One thing that has shifted in the last three appointmentsthe partisan make up of the bench. For a long time, not only was the bench white and male, but it was also disproportionately Republican. This is a heavily Democratic County, as two-thirds of the voters in 2016 voted for Hillary Clinton.

Now five of the 11 judges were appointed by DemocratsDave Rosenberg by Gray Davis in 2003, and the three most recent appointments by Jerry Brown with Dan Wolk by Gavin Newsom.

This isnt about whether or not Dan Wolk will be a good judge; he will be a judge, and hopefully he does well. This really isnt about him. It is about the process. The fact is that governors in recent years have done a good job of creating a much more diverse bench in California, and my only complaint is that when it comes to Yolo County, we have been shortchanged.

Nine white male judges in this era with 10 years of Democratic governors should not happen.

With all due respect to the last three appointments, Yolo County deserves better than to get a rash of political appointments with little regard to the overall lack of diversity of its bench.

Contrast that to San Francisco which in March elected three progressive women to its bench.It is hard to imagine two more different judicial environments, and given the notion of equal justice under the law and the fact that the vast majority of criminal defendants in Yolo County are black and browna disproportionate number, mind youit would seem that a bench more reflective of the population demographics would be fairer.

David M. Greenwald reporting

To sign up for our new newsletter Everyday Injustice https://tinyurl.com/yyultcf9

Link:
My View: Dan Wolk's Appointment to Judge Further Skews Yolo's Bench - The Peoples Vanguard of Davis

Male hypogonadism is a failure of the testes that produce the male test hormone testosterone, sperm, or both. It can be due to a testicular disorder or the result of a disease process involving the hypothalamus and pituitary gland. The male hypogonadism market is anticipated to grow owing to increasing case of testosterone deficiency among men. However, high side effects is one of the major restraints for the market growth. Moreover, rising geriatric population all across the world coupled with rising cases of obesity and rheumatoid arthritis are expected to benefit the growth of the market in the forecast period.

Some of the key players of Male Hypogonadism Market:AbbVie Inc., Allergan plc, Astrazeneca plc, Bayer AG, Eli Lilly and Company Ltd., Endo International plc., Finox Biotech,, Laboratoires Genevrier, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd.

Get Sample Copy of this Report @ https://www.reportsweb.com/inquiry&RW00013261048/sample

The Global Male Hypogonadism Market research report offers an in-depth analysis of the global market, providing relevant information for the new market entrants or well-established players. Some of the key strategies employed by leading key players operating in the market and their impact analysis have been included in this research report.

Segmentation by product type:Klinefelters Syndrome

Kallmann Syndrome

Pituitary Disorders

Others

Segmentation by Drug Delivery:Topical Gels

Injectable

Transdermal Patches

Others

Get Discount for This Report @ https://www.reportsweb.com/inquiry&RW00013261048/discount

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Male Hypogonadism market based on product and application. It also provides market size and forecast till 2027 for overall Male Hypogonadism market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America (SAM), which is later sub-segmented by respective countries and segments.

Fundamentals of Table of Content:

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered1.4 Market Analysis by Type1.5 Market by Application1.6 Study Objectives1.7 Years Considered

2 Global Growth Trends2.1 Male Hypogonadism Market Size2.2 Male Hypogonadism Growth Trends by Regions2.3 Industry Trends

3 Market Share by Key Players3.1 Male Hypogonadism Market Size by Manufacturers3.2 Male Hypogonadism Key Players Head office and Area Served3.3 Key Players Male Hypogonadism Product/Solution/Service3.4 Date of Enter into Male Hypogonadism Market3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product4.1 Global Male Hypogonadism Sales by Product4.2 Global Male Hypogonadism Revenue by Product4.3 Male Hypogonadism Price by Product

5 Breakdown Data by End User5.1 Overview5.2 Global Male Hypogonadism Breakdown Data by End User

Continue for TOC

Purchase This Report @ https://www.reportsweb.com/inquiry&RW00013261048/buying

About ReportsWeb:ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us:Call: +1-646-491-9876Email: [emailprotected]

Read the original:
Recent Facts that led Male Hypogonadism Market on top by 2027 with Top Key Players like AbbVie Inc., Allergan plc, Astrazeneca plc, Bayer AG, Eli...

The global Male Hypogonadism Therapy market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each Male Hypogonadism Therapy market player in a comprehensive way. Further, the Male Hypogonadism Therapy market report emphasizes the adoption pattern of the Male Hypogonadism Therapy across various industries.

The Male Hypogonadism Therapy market report examines the operating pattern of each player new product launches, partnerships, and acquisitions has been examined in detail.

The report on the Male Hypogonadism Therapy market provides a birds eye view of the current proceeding within the Male Hypogonadism Therapy market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Male Hypogonadism Therapy market and offers a clear assessment of the projected market fluctuations during the forecast period.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2619190&source=atm

The key players covered in this studyEli LillyPfizerAbbVieNovo NordiskMerck KGaAMylanBayerTevaNovartisAbbottRocheEndo InternationalIpsenANI PharmaceuticalsTherapeuticsMD

Market segment by Type, the product can be split intoParenteralTransdermalOralOthersMarket segment by Application, split intoHospitalsDrugstoresOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Male Hypogonadism Therapy status, future forecast, growth opportunity, key market and key players.To present the Male Hypogonadism Therapy development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Male Hypogonadism Therapy are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2619190&source=atm

The Male Hypogonadism Therapy market report offers a plethora of insights which include:

The Male Hypogonadism Therapy market report answers important questions which include:

The Male Hypogonadism Therapy market report considers the following years to predict the market growth:

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2619190&licType=S&source=atm

Why Choose Male Hypogonadism Therapy Market Report?

Male Hypogonadism Therapy Market Reportfollows a multi- disciplinary approach to extract information about various industries. Our analysts perform thorough primary and secondary research to gather data associated with the market. With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients. We address clients living in across parts of the world with our 24/7 service availability.

See original here:
Addressing the potential impact of coronavirus disease (COVID-19) on Male Hypogonadism Therapy Market : Future Growth and Challenges Analyzed Aminet...

For Avilez, the difficult adjustment is not just the result of the time she spent in prison and detention, but that she's back in her aunts house trying to live her life authentically in close quarters with some family members who haven't seen her since she transitioned to female.

"My aunt still calls me mijo. It's kind of hard for her, and I understand that. I'll have to sit down and talk with her about that later," Avilez said. "But, I want to be able to wear my makeup. I don't have to be scared no more."

Avilez lost an initial bid for asylum, but she has appealed. While she awaits her next immigration court hearing, she said she's eager to get her life started again. She wants to get a cellphone, so that she can call the friends she made in detention.

She also wants to get her job back. Avilez said she used to work in the medical field as a service technician, helping people who use wheelchairs and providing assistance to the elderly across Monterey County.

"I'm happy I'm free. [Though] I don't feel completely free because I'm wearing an ankle monitor ... I can't go out, she said.

Since Avilez left ICE custody, she has not had access to hormone treatment. But attorney Hector Vega of the San Francisco Public Defender's Office, who represents Avilez in her immigration case, said social workers in his office have found a clinic in Monterey County that can provide her the medication, free of charge.

In her first act of independence since being released from detention, Avilez bought a pink T-shirt with a single parentheses in the middle and colons dotting either side, creating the image of both a sad and happy face.

"Is it a happy face? Avilez asked. You decide if it's happy or not."

Continued here:
Released From ICE Detention Into a Pandemic: For One Woman, Returning Home Is Complex - KQED

Beauty, business, relax, repeat: Its all in a days work for British Beauty Council CEO Millie Kendall, MBE.

Subtle TweaksI totally rate Dr. Jules Nabet for tweakments. He is based at Omniya in Knightsbridge. He is a hormone specialist as well and really understands a womans face. Dr. Alexis Granite at Mallucci London is pretty incredible, too. I have watched her work and she is extremely light-handed if you want subtlety.

Freeze Frame My favorite facial would be with Su-Man Hsu at the W Hotel. She is Taiwanese, a former dancer and lives near me. She has really become a friend. Su-Man has the most unique massage techniqueit is like your face wakes up after having been asleep for years. I can top up my facials with a Bioeffect rejuvenating facial at Apogii in Notting Hill. They also have a cryo clinic and its a double-chambered one. Call me a sucker, but three minutes at minus 110 degrees Celsius can do wonders for your body. Plus, it is large enough so you can take some friends in with you for moral support.

Charlotte Tilbury, of course, the darling of British Beauty; Pat McGrath Labs, the mother of British Beauty; Aromatherapy Associates is simply my favorite bath and body brand. Deep Relax is divine and the most recognizable, but equally unique, scent.

Destination: RelaxationMy favorite massage is a deeply relaxing Aromatherapy Associates full body with Rika at the Mandarin Oriental Hotel. The spa is just so chic.

One-Stop Shop For workouts, I have a personal trainer, but I love the Reformer Pilates classes at Frame. I go to the one near our offices on Berners Street. There is a Hershesons hair salon above it, so you can get your hair done afterwardsand you can also choose from one of the many amazing additional services, like DryBy nails, SumanBrows, Ministry of Waxing, etc. It is literally a mecca. Then, around the corner is Nicola Clarke for John Frieda; Nic has been coloring my hair forever and I visit there on a very regular basis for a top-up of blond.

Gut CheckIf you want nutritional support or a colonic, see Kaori Murphy at the Hale Clinic. She is amazing at getting your gut health on track. She is extremely strict with you, but gentle, too. I saw her for months at one pointevery Friday morning I had to go see her. She honestly changed my life.

Arabellas Votary skin-care range is so loved by makeup artistsprobably because her oils are really light and wearable; The frankincense line from Neals Yard Remedies is amazing, and their farm and manufacturing facility are spectacular; Sam McKnights Cool Girl Barely There Texture Mist makes you look and feel like Kate Moss; I love anything from The Body Shop the original renegade brand; Theres a new British hair-care brand based on Ayurveda called Chmpo, which is the Indian word for shampoo.

At NewBeauty, we get the most trusted information from the beauty authority delivered right to your inbox

Find a NewBeauty "Top Beauty Doctor" Near you

Read more:
National Treasures: Millie Kendall Recommends the Best Beauty Buys London Has to Offer - NewBeauty Magazine

publication date: May. 1, 2020

Howard A. Skip Burris III, MD, FACP, FASCO

President, American Society of Clinical Oncology

President, Clinical Operations and Chief Medical Officer

Sarah Cannon, the Cancer Institute of HCA Healthcare

Associate, Tennessee Oncology

This story is part of The Cancer Letters ongoing coverage of COVID-19s impact on oncology. A full list of our coverage, as well as the latest meeting cancellations, is availablehere.

The COVID-19 pandemic will change the structure and economics of clinical care and clinical trials in cancer, said Howard Skip Burris, president of clinical operations and chief medical officer of Sarah Cannon, the Cancer Institute of HCA Healthcare.

The pandemic is going to create an opportunity to look at how oncology should be reimbursed and how a practice is not disadvantaged when theyre able to function electronically in some areas, said Burris, who is this years president of the American Society of Clinical Oncology. And then I think bigger picture, this pandemic will help us set some health care priorities for the population.

Im hopeful that after we get through the storm, there will be a real assessment and look at the data as you alluded to about the need to continue with appropriate cancer screening programs, mammography, colonoscopy, and appropriate CT scans.

And hopefully, we wont see too big of a disadvantage coming from procedures being delayed. The information during this time will help confirm what we thought for yearsthat early detection of cancer really leads to better outcomes. These few months here, I think, are going to greatly shape how we approach health care over the next few years.

Burris spoke with Paul Goldberg, editor and publisher of The Cancer Letter.

Paul Goldberg:

First of all, how are you?

Skip Burris:

Im doing well. We are staying fairly busy in continuing to care for our patients. Nashville had a lot of cases, but we have had a fairly low number of hospitalizations and an even lower number of deaths. So, weve been a little bit of an outlier as a state.

Nashville had a lot of cases early, but the hospitals have been relatively quiet in comparison to other states. The major hospitals here have been running inpatient COVID-positive numbers in the twenties, with a handful of patients in the intensive care unit.

PG:

How about your practice? How about Sarah Cannon?

SB:

Our major practices are Tennessee Oncology and Florida Cancer Specialists, where we have the bulk of the patients on clinical trials. We also have research programs in Kansas City, Oklahoma City and Denver.

We have about a dozen COVID-19 positive patients across the practices, and have been fortunate that none have been critically ill. A few staff have been infected, exposed outside of our clinics, but again, nobody critically ill.

The Nashville clinic, where I practice, is relatively quiet, but we are continuing treatment. Surveillance visits have been moved out a few months, and were continuing to keep an eye on that timing. The benign hematology has also been moved out. The oral therapies are being handled with telemedicine and shipping the drugs to the patients.

The clinics across our network are steadily functioning, but not overly busy, including chemotherapy rooms. With the lower volume, we are able to successfully implement social distancing measures as well as all the safety precautions of masks, gloves, and hand washing.

PG:

What about the financial impact? Are you seeing any?

SB:

There is an impact, but its a little early to do any calculations. The absolute visits are going to be dropping. We are starting to pick up the telemedicine visits, but its probably 50/50 on patients being comfortable with that approach versus simply wanting to push out their visit. The treatments have remained fairly steady in terms of those patients that are on intravenous treatments.

I think the financial impact is not going to be quite as devastating as we had first anticipated. The missed visits will never be made up.

Its a little bit like the movies and the restaurant businesspeople are not going to have two dinners at the same place in the same night, or see two movies at the same timepatients are not going to come for two visits to our clinics in a week either. So, I think the financial impact is going to be substantial, but not catastrophic.

I do think it is different for large practices versus the smaller practices. I worry about some of the smaller practices, with a handful of physicians, and their ability to have staying power through this pandemic, as they may not have the ability to handle the decrease in volume.

PG:

What about impact on clinical trials, especially drug company trials? Weve certainly written a lot about NCI trials, but drug company trials, I think havent been really gauged yet. What impact do you think this will have on approvals?

SB:

Its an interesting question. We have seen big pharma that are conducting global trials pause studies and put a hold on accrual. I think a part of that is making sure that they can get the data.

Also, it was easier to not make site-specific selections and just put a large trial on hold. So, weve seen most of the big pharma react that way.

We have seen a substantial drop in enrollment for phase II/III studies, resulting from at least a third of the clinical trial menu being put on pause.

The other part about the phase II/III side of the businesses is, in many of those scenarios, patients have an option. We have had so many approvals recently. Patients may have an off-study option that might require fewer visits or less travel. I suspect that is impacting accrual as well.

All of those will be detrimental in terms of slowing down trial completion, slowing down approvals.

On the other hand, on the phase I end of the spectrum, where I think the majority of the patients are seeking an investigational treatment and/or a treatment to match their mutation, we have not seen quite the level of decline.

And in particular, we have seen the smaller biotechs continue forward. Many of their phase I trials are at only a handful of sites, making any decisions site-specific.

As you said at the beginning, in terms of approvals, certainly many of the phase II/III studies are going to be slowed substantially. It is also important to note that some of the big academic centers, typically accruing many patients, are in cities hit the hardest by COVID-19, such as New York City, Boston and some of the cities in Europe, which is impacting trials.

PG:

You would think that some patients would have to be censored out, because with time to progression, the radiographic metrics, you would pretty much have missed the opportunity to gauge it; right?

SB:

Correct. I think its going to be complex within the phase II/III trials. I was reading The Cancer Letter with Matt Ongs interview with Don Berry [The Cancer Letter, April 24, 2020], thinking about how individuals will need to come in and really think about how we pool that data and analyze it. But youre exactly right.

The NCI has been great in encouraging taking deviations related to COVID-19 needed to keep the patient on study. We have made a number of operational adjustments including remote data monitoring, shipping pills to keep people on oral therapies, and implementing telemedicine visits.

Certainly, in the phase II/III area, with time to progression studies, there will be an impact, and there will be some complexities in how we analyze that data.

PG:

How are academic cancer centers affected?

SB:

Probably a lot depends on where they are located geographically. In talking to our colleagues at centers in New York, Boston and New Haven, we know many of those centers have had to stop clinical trial accrual. We are seeing the same thing in much of the East Coast and parts of the West Coast.

Also, there is a tertiary referral travel population. We have seen, at all of our centers, patients being much more hesitant to travel for treatment. I think it will substantially impact analyzing the data from those centers and getting those trial programs up and running.

Some of the academic medical centers have had a higher volume of COVID-19 positive patients. I know Ive had some patients that have gone back and forth to MD Anderson, where they are now encouraging patients to stay there in Houston, and not travel for their safety.

This recommendation gets into socioeconomic issues about who can do this relocation and who cannot.

PG:

What impact do you think it will have financially on the academic cancer centers?

SB:

I think you have to look at an academic medical center as part of a larger hospital. We can break this into different bucketssmall community practices will be hit differently than larger community practices that have more synergies.

Larger practices may have better staying power, and, of course the CARES program allows the hospitals to help in some ways. There are some waivers with regard to Stark concerns, and then the ability for some of these practices to participate in the PPP programs for loans and for advanced Medicare payments.

When you think about the hospitals right now, they are essentially doing emergency room care, which has dropped, COVID-19 care thats ongoing, and then cancer care that needs to be done.

The other services generating revenues have slowed down because many of the procedures, such as orthopedics and cardiovascular can be pushed out a few months. We have seen across the country health systems and hospital systems beginning to furlough individuals and take other actions with regard to employment.

I think that this environment is going to be tough for the academic medical centers. Hospitals have multiple sources of revenue, and many of these sources have really been scaled back as patients choose to defer coming in or there are simply not the resources for routine health care.

PG:

So, there is redistribution, but is it a net loss?

SB:

It will be interesting to see how some of that care comes back. While patients will never make up that cancer visit, the patients who need a hip replacement will schedule their surgery.

The individuals who need a valve replacement will get their cardiac procedure. I think in other specialties there will be a backlog, and it will be interesting as we go through the summer and the fall to see how that is handled. There is some short-term pressure in terms of just how much routine health care has paused or slowed down.

It has been interesting to see the articles talking about all the patients who used to come into the emergency room or the urgent care centers for aches and pains, and how much that has dropped. And then we are going to wonder going forward, will patients be more hesitant to utilize the health care system? Will they think once or twice before coming in?

As you have alluded to, we also have the economic side: we are seeing the unemployment numbers go up, which may have short-term impact as well. We have many Americans, unfortunately, uninsured or with less health insurance than they have had in the past.

PG:

What about the impact on community hospitals and for-profit hospitals?

SB:

Sarah Cannons parent company is HCA Healthcare, and they have committed to not laying off anyone through this crisis. HCA Healthcare is a large company, with the financial strength to support pandemic pay programs that will aid employees.

County hospitals or rural community hospitals are impacted on a different level. They already were under economic pressures. I suspect we may see some consolidation and closures of hospitals in rural settings or in places that are geographically disadvantaged.

That issue is going to be a stressor to the system. We already were trying to figure out how to do rural health care before the pandemic, and this crisis has certainly exacerbated the challenge.

Hospitals that do not have a large system to help alleviate some of the stress are going to be struggling to get through the near term.

PG:

I was just looking at what seems to be happening in the adjuvant care. There seems to be a shift to neo-adjuvantbecause of COVID. Is there data to support this in terms of safety and efficacy?

SB:

That is a great question, and I say that because I have asked the same question. In certain settings, such as HER2 positive breast cancer, there are a number of patients who would likely benefit from neoadjuvant therapy, as well as some triple-negative or locally advanced tumors.

There are likely other subsets of breast cancer and other diseases where neoadjuvant therapy makes sense. But by and large, you are correct, that during this COVID-19 crisis, many think it is better to put patients through chemotherapy versus surgery. And that has been greatly debated.

CMS came out with guidelines that put cancer surgery in the Tier Three category, and that seems reasonable. Our motto at Sarah Cannon has been that we are going to stay safe and stay the course.

We have seen a number of surgeries put off, but I do not think I have ever said to a patient with invasive cancer that their surgery is elective. Some are more urgent than others.

The system has made a quick shift to thinking that neoadjuvant therapy is the safest thing to do or the best thing to do, but there is not a lot of data to back that up in many settings. We have never really had clinical trials that showed that hormonal therapy was a great neoadjuvant treatment for the hormone-positive breast cancer. It is a real judgment call to put patients through chemotherapy, with myelosuppression and more in this setting.

There were some broad-based recommendations made from several societies that I found interesting, without a lot of data to back them up.

PG:

Will we learn from this, or will this be one of those societal experiments that we will never know the impact of?

Read more:
Skip Burris: These few months are going to shape health care in the coming years - The Cancer Letter

The world lost another brilliant actor, Irrfan Khan, on April 29, 2020. He was admitted to Mumbais Kokilben hospital intensive care unit, with a colon infection, the day prior. His condition deteriorated quickly and took a turn for the worse. He was 53 years old at the time of his death.

In 2018, he was diagnosed with a neuroendocrine tumor. This is a type of cancer that begins in specialized cells called neuroendocrine cells. These cells have similar traits to those of hormone-producing cells and nerve cells. Neuroendocrine tumors are rare and normally form in the appendix, pancreas, small intestine, rectum, or lungs.

Khan was born in Jaipur, Rajasthan, India, on Jan. 7, 1967. His full name at birth is Sahabzade Irrfan Ali Khan. He was an amazing cricket player. Khan was selected for the CK Nayudu Tournament. However, due to a lack of funds, he was unable to attend.

He decided to focus his attention on acting. The beloved actor earned himself a scholarship to the National School of Acting located in New Delhi, in 1984. His acting career started out in Bollywood where he was in Haasil, Maqbool, and the Namesake to name a few movies.

Khan showed the world how adaptive he was when he took on his various roles. His exquisite style showed the world a man who could be charming, clever, and at times maniacal and dangerous. During his decades-long career, he won his way into many fans hearts.

His rise to international fame came with his role in the movie Slumdog Millionaire. This movie won seven BAFTAs and eight Academy Awards. Khan also had memorable roles in other movies such as, Jurassic World, Life of Pi, and The Amazing Spiderman.

Many people went to social media to voice how Khan had touched them with his acting. He has left behind his beloved wife Supta, and their sons Ayaan and Babil.

By Sheena RobertsonEdited by Jeanette Vietti

Sources:

IMDB: Irrfan KhanMayo Clinic: Neuroendocrine tumorsIndian Express: Irrfan Khan (1967-2020): An actor whose brilliance made everything betterYahoo: Slumdog Millionaire and Life of Pi star Irrfan Khan dies at 53MSN: Irrfan Khan, Life of Pi, and Slumdog Millionaire Star Dies at 53The Daily Beast: Irrfan Khan, Life of Pi and Slumdog Millionaire Star, Dies at Age 53

Top and Featured Image Courtesy of Herry Lawfords Flickr Page Creative Commons LicenseInline Image by Bollywood Hungama Courtesy of Wikimedia Commons Creative Commons License

death, khan, Slumdog Millionaire, spot

Read this article:
Irrfan Khan, International Superstar, Passed Away at the Age of 53 - Guardian Liberty Voice

By its very definition, medicine saves lives by treating or preventing diseases. But now, some in the media are distorting its meaning to include abortion the ending of anothers life.

On April 28, The New York Times published a piece examining, Abortion by Telemedicine. In the story, health and science writer Pam Belluck cited several women who obtained abortions through TelAbortion, a telemedicine program that provides video consultations with abortion providers so that pregnant women can take abortion pills on their own without having to visit an actual clinic. Both TelAbortion and Belluck recognized the pills that cause abortion as medications.

One of the women interviewed for the piece, Ashley Dale, allowed the Times to sit in on her video consultation.

The doctor explained that two medicines that would be mailed to Ms. Dale would halt her pregnancy and cause a miscarriage, Belluck described.

Bellucks wording mirrored the abortion industrys embrace of euphemistic language surrounding abortion. But theres a difference: Medicine saves human lives; abortion ends them. Miscarriage isnt a choice; abortion is.

In order to distinguish from surgical abortion, many in the media refer to medication abortion as an abortion administered by pill. But only recently havemajor outlets begun using phrases such as abortion medication to call abortion itself a type of medicine.

Belluck described what happens in this particular type of abortion.

[D]octers explain that most women do not experience discomfort from mifepristone, which blocks a hormone necessary for pregnancy to develop, she wrote. Cramping and bleeding, resembling a heavy period, occur after the expulsion of fetal tissue caused by the second drug, misoprostol, which is taken up to 48 hours later.

Thats not how all doctors describe it. Dr. Anthony Levatino, an obstetrician-gynecologist who once performed more than 1,200 abortions, partnered with pro-life group Live Action in 2016 todetail abortion procedures. Medical abortion, he said, consists of two steps.

At the abortion clinic or doctors office, the woman takes pills which contain Mifepristone, or RU-486, he began. RU-486 blocks the hormone progesterone and causes the lining of the mothers uterus to break down, cutting off blood and nourishment to the baby.

In the second step, the woman takes Misoprostol, or Cytotec, a day or two later. Taken together, RU-486 and Misoprostol cause severe cramping, contractions, and often heavy bleeding to force the dead baby out of the womans uterus, he added.

If the abortion takes place at nine weeks, he said, her baby will be almost an inch long and she might even be able to distinguish his or her fingers and toes.

Even so, theNew York Timespiece regularly referred to these abortion pills as medication. One photo caption showed Ashley Dale taking medications that were mailed to her.

At one point, Belluck described how one woman went on an engagement photo shoot with her fianc after taking the first medication and then took the second medication that evening.

She continued to use the phrase medication and even the two-medication regimen in her piece.

Abortion through medication, first approved by the F.D.A. in 2000, is increasingly becoming womens preferred method, she wrote.

Or is it? Several of the women appeared to choose abortion because they felt like it was their only choice.

Dale, the first woman Belluck mentioned in her piece, said she would love to have another baby, but circumstances involving an estranged boyfriend had made the choice clear.

Another woman, Lee, decided to terminate the pregnancy because she had recently cut ties with her boyfriend after he was arrested on drug charges.

And Leigh, who self-identified as pro-life, turned to abortion because she has depression, which became so severe after she had a baby two years ago that she sometimes felt suicidal, wrote Belluck.

In a follow-up call after her abortion, Leigh said she felt compelled to abort no matter how much I hate myself, Belluck reported. Even now, when she sees another baby, she asks herself, Did I make the wrong choice?

I wanted to keep my baby, but I just couldnt, she added.

Abortion and medicine are opposing terms; not interchangeable ones. Medicine promotes the welfare of human beings and saves lives every day. Abortion destroys a life that, from the moment of conception,contains a unique set of DNA. Instead of being a disease to fight, the unborn child is a patient to protect.

But heres one thing that even themedia can agree on: An unborn babys heart often begins beating before a mother even knows shes pregnant. Abortion stops it.

Read the original:
Dear Media: Abortion Is Not Medicine - Townhall

Direct-to-consumer Genetic Testing Market Insights 2018, is a professional and in-depth study on the current state of the global Direct-to-consumer Genetic Testing industry with a focus on the Global market. The report provides key statistics on the market status of the Direct-to-consumer Genetic Testing manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2018-2025 global Direct-to-consumer Genetic Testing market covering all important parameters.

The report on the Direct-to-consumer Genetic Testing market provides a birds eye view of the current proceeding within the Direct-to-consumer Genetic Testing market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Direct-to-consumer Genetic Testing market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Direct-to-consumer Genetic Testing market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2644650&source=atm

The key points of the Direct-to-consumer Genetic Testing Market report:

The report provides a basic overview of the Direct-to-consumer Genetic Testing industry including its definition, applications and manufacturing technology.

The report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2018-2025 market shares for each company.

Through the statistical analysis, the report depicts the global total market of Direct-to-consumer Genetic Testing industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.

The report then estimates 2018-2025 market development trends of Direct-to-consumer Genetic Testing industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out.

The report makes some important proposals for a new project of Direct-to-consumer Genetic Testing Industry before evaluating its feasibility.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2644650&source=atm

There are 3 key segments covered in this report: competitor segment, product type segment, end use/application segment.

For competitor segment, the report includes global key players of Direct-to-consumer Genetic Testing are included:

Regional and Country-level AnalysisThe report offers an exhaustive geographical analysis of the global Direct-to-consumer Genetic Testing market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.Competition AnalysisIn the competitive analysis section of the report, leading as well as prominent players of the global Direct-to-consumer Genetic Testing market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Direct-to-consumer Genetic Testing market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Direct-to-consumer Genetic Testing market.The following players are covered in this report:23andMeMyHeritageLabCorpMyriad GeneticsAncestry.comQuest DiagnosticsGene By GeneDNA Diagnostics CenterInvitaeIntelliGeneticsAmbry GeneticsLiving DNAEasyDNAPathway GenomicsCentrillion TechnologyXcodeColor GenomicsAnglia DNA ServicesAfrican AncestryCanadian DNA ServicesDNA Family CheckAlpha BiolaboratoriesTest Me DNA23 MofangGenetic HealthDNA Services of AmericaShuwen Health SciencesMapmygenomeFull GenomesDirect-to-consumer Genetic Testing Breakdown Data by TypeDiagnostic ScreeningPrenatal, Newborn Screening, and Pre-Implantation DiagnosisRelationship TestingDirect-to-consumer Genetic Testing Breakdown Data by ApplicationOnlineOffline

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2644650&licType=S&source=atm

Reasons to Purchase this Report:

* Estimates 2018-2025 Direct-to-consumer Genetic Testing market development trends with the recent trends and SWOT analysis

* Market dynamics scenario, along with growth opportunities of the market in the years to come

* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects

* Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.

* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years

* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

See original here:
Potential Impact of COVID-19 on Direct-to-consumer Genetic Testing Market Growth, Size, Share and Forecast 2020-2059 Aminet Market Reports -...